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Objective Despite advances in the identification of epigenetic alterations in pancreatic cancer, 
their biological roles in the pathobiology of this dismal neoplasm remain elusive. Here, we 
aimed to characterize the functional significance of histone lysine methyltransferases (KMTs) 
and demethylases (KDMs) in pancreatic tumourigenesis.   
Design DNA methylation sequencing and gene expression microarrays were employed to 
investigate CpG methylation and expression patterns of KMTs and KDMs in pancreatic cancer 
tissues versus normal tissues. Gene expression was assessed in five cohorts of patients by 
reverse transcription quantitative-PCR. Molecular analysis and functional assays were 
conducted in genetically modified cell lines. Cellular metabolic rates were measured using an 
XF24-3 Analyzer, while quantitative evaluation of lipids was performed by liquid 
chromatography-mass spectrometry (LC-MS) analysis. Subcutaneous xenograft mouse 
models were used to evaluate pancreatic tumour growth in vivo. 
Results We define a new anticancer function of histone lysine (K)-specific methyltransferase 
2D (KMT2D) in pancreatic cancer. KMT2D is transcriptionally repressed in human pancreatic 
tumors through DNA methylation. Clinically, lower levels of this methyltransferase associate 
with poor prognosis and significant weight alterations. RNAi-based genetic inactivation of 
KMT2D promotes tumor growth and results in loss of H3K4me3 mark. In addition, KMT2D 
inhibition increases aerobic glycolysis and alters the lipidomic profiles of pancreatic cancer 
cells. Further analysis of this phenomenon identified the glucose transporter SLC2A3 as a 
mediator of KMT2Dinduced changes in cellular, metabolic and proliferative rates. 
Conclusion Together our findings define a new tumor suppressor function of KMT2D through 
the regulation of glucose/fatty acid metabolism in pancreatic cancer. 
 
WHAT IS ALREADY KNOWN ON THIS SUBJECT? 
• Pharmacological targeting of epigenetic modifications contributes to uncovering 
therapeutic opportunities in pancreatic cancer. 
• Several groups describe the deregulation and functional diversity of some histone 
methylation pathways in pancreatic adenocarcinomas. 
• To date, the biological and translational significance of the aberrant function of the 







WHAT ARE THE NEW FINDINGS? 
• Transcriptional repression of histone lysine (K)-specific methyltransferase 2D 
(KMT2D) is double site, CG methylation-dependent. 
• Pancreatic cancer growth is promoted by KMT2D downregulation. 
• KMT2D suppression mediates loss of H3K4me3 signals in metabolic pathways and 
accounts for an induction of aerobic glycolysis and lipid levels. 
• SLC2A3 (also known as GLUT3) is a mediator of KMT2D-induced effects in cellular 
metabolic and proliferative rates. 
• Patients with pancreatic cancer harbouring low KMT2D levels have worse prognosis 
and significant weight/body mass index (BMI) alterations. 
 
HOW MIGHT IT IMPACT ON CLINICAL PRACTICE IN THE FORESEEABLE FUTURE? 
• Characterization of KMT2D-associated metabolic signatures provides a new molecular 
rationale to identify and develop a new generation of therapeutic agents. 
• Future studies exploring the causal molecular link between KMT2D expression and 
clinical outcomes may offer prognostic information and insights into pancreatic 
tumourigenesis and progression. 
 
INTRODUCTION 
Emerging studies demonstrate that epigenetic rather than genetic changes modulate the 
phenotype of different cancer types, specifically the ones controlling chromatin modifications 
such as histone methylation. In fact, there is evidence showing that changes in histone lysine 
methyltransferases (KMTs) and demethylases (KDMs), including KDM2B1 and EZH2,2 could 
affect pancreatic tumour growth. This is particularly important as it has been recently indicated 
that KMTs and KDMs could alter gene expression in a selective manner, while other chromatin 
modifiers, such as histone deacetylases and DNA methyltransferases, globally regulate gene 
expression.3 Thus, understanding the function of histone methylation pathways could lead to 
a high degree of specificity in targeting specific epigenetic factors that control pancreatic 
malignant transformation. 
In the present study, we provide evidence for a novel role of histone lysine (K)-specific 
methyltransferase 2D (KMT2D) in pancreatic carcinogenesis. Our chromatin 
immunoprecipitation- sequencing (ChIP-seq) and genome-wide gene expression analysis, as 
well as tumour growth studies, strongly support its role as a pancreatic tumor suppressor. 
Specifically, KMT2D inhibition results in alterations of pancreatic cancer cells’ bioenergetic 
and lipidomic profiles, by increasing aerobic glycolysis and lipid levels. Clinical outcomes 
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across the range of body weight and body mass index (BMI) were found to significantly 
correlate with KMT2D expression levels. Taken together, we have defined a previously 
uncharacterized function of KMT2D as growth-limiting factor in pancreatic cancer, and by 
mechanistic studies we demonstrate that the metabolic reprogramming underlies this 
anticancer function of KMT2D. 
 
MATERIALS AND METHODS 
Cell treatments. 
Cells were transfected with small interfering RNAs (siRNAs) for KMT2D, #1 (s15605) and #2 
(s15604), SLC2A3 (s12933), LDLR (s224008), SLC2A1 (s12926), mTOR (s604), RICTOR 
(s226000) and control (4390846) using Lipofectamine RNAiMax Transfection Reagent 
(13778150, Life Technologies). Lentiviruses were produced in HEK293T cells (ATCC) 
transfected with the packaging and expression constructs using Fugene 6 (E2691, Promega). 
Cells were infected with the viruses using DEAE-Dextran and selected with puromycin. 
Mouse experiments. 
Cells were transduced with short hairpin RNAs (shRNAs) for KMT2D or scramble (1864, 
Addgene) lentiviral expressing constructs. Sequences containing the shRNAs for KMT2D 
were annealed and cloned into the pLKO.1 puro (8453, Addgene) vector according to the 
Janes Lab protocol (http:// bme. virginia. edu/ janes/ protocols/ pdf/ Janes_ shRNAcloning. 
pdf): 
#1–19: (sense: CCGG GAGT CGAA CTTT ACTG TCTC TGCA GAGA CAGT AAAG TTCG 
ACTC TTTTTG; antisense: AATT CAAA AAGA GTCG AACT TTAC TGTC TCTG CAGA 
GACA GTAA AGTT CGACTC). 
#2–19: (sense: CCGG CCAC TCTC ATCA AATC CGAC TGCA GTCG GATT TGAT GAGA 
GTGG TTTTTG; antisense: AATT CAAA AACC ACTC TCAT CAAA TCCG ACTG CAGT 
CGGA TTTG ATGA GAGTGG). 
#1–21: (sense: CCGG GAGT CGAA CTTT ACTG TCTC CCTG CAGG GAGA CAGT AAAG 
TTCG ACTC TTTTTG; antisense: AATT CAAA AAGA GTCG AACT TTAC TGTC TCCC 
TGCA GGGA GACA GTAA AGTT CGACTC). 
#2–21: (sense: CCGG CCAC TCTC ATCA AATC CGAC ACTG CAGT GTCG GATT TGAT 
GAGA GTGG TTTTTG; antisense: AATT CAAA AACC ACTC TCAT CAAA TCCG ACAC 
TGCA GTGT CGGA TTTG ATGA GAGGG). 
3.5*106 or 4.5*106 MIA PaCa-2 or CAPAN-2 cells were injected subcutaneously at the right 
flank of NOD-SCID mice (five mice/group). Tumor volume was monitored every week for up 
to 42 and 84 days, respectively. Tumour volumes were calculated through the formula V (mm3) 
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= axb2/2, where a is the largest diameter and b is the perpendicular diameter. Bars represent 
mean ± SD. 
Data availability section. 
Array and sequencing data have been deposited in the Gene Expression Omnibus database 
(http://www. ncbi. nlm. nih. gov/geo/). Gene expression array, targeted bisulfite sequencing 
and ChIP-seq data are available under the following accession numbers: GSE85991, 
GSE85961 and GSE85886. Additional materials and methods are included as part of the 
online supplementary materials and methods section. 
 
RESULTS 
KMT2D exerts tumor suppressive activities in pancreatic cancer. 
To define the role of KMTs and KDMs in pancreatic carcinogenesis, we initially determined 
the levels of these enzymes in tumours (n=14) and adjacent controls (n=8) and found different 
members of the KDM family (KDM2A, KDM4C, KDM5B, KDM8), SETD family (SETDB2, 
SETD6), and the SUV420H1 and KMT2D to be differentially expressed (online supplementary 
table S1). As shown in Figure 1A and supplementary figure S1A, statistically significant and 
consistent deregulation of gene expression was observed only for KMT2D in three 
independent patient cohorts. We further investigated the differential KMT2D expression based 
on previously published gene expression array data listed in the Oncomine database. Notably, 
KMT2D mRNA expression displays significantly decreased levels based on two independent 
studies 4 5 (supplementary figure S1B, C). The expression of other H3K4 methyltransferase 
genes sharing similar structural domains with KMT2D was also measured. As shown in online 
supplementary figure S1D, E, no significant changes were observed in the mRNA levels of 
neither KMT2B nor KMT2C in the human pancreatic cancer samples used in the current study.  
Based on the above findings, we postulated the hypothesis that KMT2D might display tumor 
suppressive properties in pancreatic cancer. To address this hypothesis, we performed a 
series of in vitro and in vivo experiments where KMT2D was genetically inactivated, as 
evidenced in figure 1B. Transient downregulation of KMT2D by using two different siRNAs 
promoted cellular proliferative capacity (figure 1C, online supplementary figure S1F, G and 
supplementary tables S2–S3). To confirm the biological significance of KMT2D, pancreatic 
cancer cells stably suppressed of KMT2D expression were established (online supplementary 
figure S1H) and tested for their proliferative capacity (online supplementary figures S1I–L). 
The most efficient shRNA transfected cell population (#2–21) was subjected to clonal selection 
and used for further studies. Reverse transcription quantitative-PCR (RT-qPCR) and 
immunoblot (IB) analysis were used to verify the lower levels of KMT2D mRNA and protein in 
the clonal cell lines (figure 1D). Similar to transient knockdowns, stably decreased KMT2D 
6 
 
expression led to increased MIA PaCa-2 proliferation (figure 1E, online supplementary figure 
S1M, N and supplementary tables S4–S5) and cell anchorage-independent growth (figure 1F 
and online supplementary figure S10). 
To further validate our hypothesis, the effects of KMT2D inhibition of expression were 
investigated in nude mice bearing human pancreatic cancer xenografts. Significant induction 
of tumor growth rate and weight was observed (figure 1G, H and online supplementary figure 
S1P, Q), and lower KMT2D mRNA levels were confirmed by RT-qPCR and 
immunohistochemical (IHC) analysis (supplementary figure S1R, S) in the excised tumours. 
Consistent with these observations, histopathological analysis of tumours from different mice 
at the endpoint revealed high proliferation rates, as evidenced by Ki-67 immunostaining (figure 
1i). Taken together, these in vitro and in vivo results point towards a tumour suppressive role 
of KMT2D in pancreatic cancer. 
Site specific DNA methylation associates with KMT2D transcriptional repression. 
We then sought to determine the mechanism underlying KMT2D decreased expression in 
pancreatic cancer. To this end, we designed a complementary tissue-based and cell-based 
experimental approach for the evaluation of KMT2D transcriptional repression dependency on 
DNA methylation, as depicted in Figure 2A. We have investigated DNA methylation patterns 
of KMTs and KDMs in 20 pancreatic cancer tissues compared with 13 adjacent control tissues 
by using the Infinium Human Methylation 450 Bead ChIP Array. KMT2D, together with other 
four of these enzymes, was found to be significantly differentially methylated (at least over 
25%) in pancreatic tumours compared with normal tissues (figure 2B and supplementary Table 
S6). Specifically, methylation of two individual CpG motifs was observed at nucleotides (nt) 
−29 and +45, relatively to the KMT2D transcription start site (TSS). By integrating the data 
originating from CpG methylation genome-wide analysis with gene expression profiling in 
cancerous versus normal pancreas, KMT2D was simultaneously identified to be 
hypermethylated and downregulated. Whole exome sequencing in the pancreatic cancer cell 
lines used in the current study (online supplemetary table S7), as well as published data from 
other groups, show that KMT2D harbours deletions and mutations in pancreatic ductal 
adenocarcinoma (PDAC); however, the actual frequencies of such mutations in PDAC are still 
debatable. 6, 7 Given the above, we cannot rule out the possibility that genetic inactivation of 
KMT2D relies partly on both its mutational and/or CpG methylation status. 
Next, targeted bisulfite sequencing was performed for the specified region comprising nt −179 
to +122, in a panel of five pancreatic cancer cell lines treated with the DNA methyltransferase 
inhibitor 5-AZA-2'-deoxycytidine (5-AZA-CdR, Decitabine). Boxplots of DNA methylation 
levels indicate that drug-treated cells have an extensive hypomethylated pattern (figure 2C 
and online supplementary figure S2A). Further evidence on the impact of CpG methylation to 
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repress KMT2D transcriptional activity was obtained from analysis of KMT2D mRNA levels on 
different exposure times and drug concentrations (figure 2D and online supplementary figure 
S2B). The most robust time-dependent and dose-dependent changes occurred in MIA PaCa-
2 and AsPC-1 cell lines, an observation that was further validated by IB analysis (figure 2E). 
However, since this agent induces genome-wide demethylation, the observed increase in 
expression after treatment could be indirect. To eliminate this possibility, we designed a 
luciferase reporter assay for in vitro methylated KMT2D genomic region of interest (ROI) in 
wild-type or mutated state (figure 2F). Linearized constructs were in vitro methylated with high 
efficiency, as evidenced by resistance to digestion with HpaII methylation-specific 
endonuclease (figure 2G). As proof of concept, no significant differences were found among 
the promoter activity of unmethylated inserts (serving as positive controls), while in the totally 
unmodified methylated insert Renilla luciferase reporter (hRluc) gene activity was almost 
absent, thus confirming that CpG methylation controls transcriptional repression of KMT2D. 
Remarkably, both mutations applied in the ROI seem to derepress the hRluc activity of the in 
vitro methylated constructs by approximately 22-fold or 12-fold for Mut 1 and Mut 2, 
respectively (figure 2H, I). Taken together, our results identified that single-site CpGs 
methylation is critical for the suppression of KMT2D expression levels in pancreatic cancer. 
KMT2D suppression promotes a metabolic shift to aerobic glycolysis through 
regulation of SLC2A3. 
Next, we investigated the mechanisms downstream of KMT2D underlying its tumor 
suppressor functions. KMT2D belongs to the complex of proteins associated with Set1 
(COMPASS) family of H3K4 methyltransferases8; thus, we first examined the effects of 
KMT2D on global H3K4 methylation marks in pancreatic cancer cells. Using IB we showed 
that H3K4 mono-methylated and di-methylated were slightly downregulated in the siKMT2D 
treated cells, while the tri-methylated form of H3K4 (H3K4me3) was significantly reduced 
(figure 3A). Furthermore, we tested the effect of 5-AZA-CdR treatment, as a mean to 
overexpress KMT2D, on the H3K4me3 levels of pancreatic cancer cells. Consistent with the 
notion that H3K4 methylation is enriched on 5-Aza-dCdR treatment, potentially as a secondary 
event following the promoter demethylation and gene re-expression,9 10 we observed a 
remarkable enrichment of H3K4me3 methylation upon agent treatment. Interestingly, silencing 
of KMT2D in 5-Aza-dCdR-treated cells did not decrease H3K4me3 methylation levels as 
efficiently as in untreated cells, most possibly due to higher KMT2D levels (online 
supplementary figure S3A, B), while non-significant alterations in H3K4me1/2 levels were 
observed (online supplementary figure S3C). To complement these initial findings, ChIP-seq 
analysis for H3K4me3 and microarray gene expression profiling were performed in MIA PaCa-
2 cells. ChIP-seq analysis showed significant decrease in H3K4me3 signals in KMT2D-
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silenced versus non-targeting control cells (Figure 3B). The H3K4me3 peaks significantly 
overlap between the two different siRNAs used, as shown by the Venn diagram (figure 3C). 
H3K4me3 peaks were associated mostly with intergenic and intronic regions and were located 
around the TSS site (figure 3D, E). Marked loss of H3K4me3 peaks also occurs in loci 
essential for gene transcription as in the case of the general transcription factor IIA subunit 1 
(GTF2A1), a component of the transcription machinery of RNA polymerase II that plays an 
important role in transcriptional activation (online supplementary figure S4). Gene ontology 
(GO) analysis of the H3K4me3 peaks found to be diminished on KMT2D silencing identified 
association with transcription-related pathways, with the highest enrichment score being 
observed for ‘transcription from RNA polymerase II promoter’ and ‘metabolic processes’ 
(figure 3F). Serine/Threonine kinase 11 (STK11) represents an example of KMT2D-mediated 
regulation of metabolic gene through reduction of H3K4me3 occupancy that was further 
experimentally validated as a direct regulatory target of KMT2D (online supplementary figure 
S5). Gene expression studies demonstrated 1035 genes to be downregulated, while a smaller 
subset of genes was upregulated on KMT2D suppression (figure 3G). We mapped the 
differentially regulated genes to well-established (canonical) pathways by using the Ingenuity 
Pathway Analysis (IPA) software (Ingenuity Systems, http://www. ingenuity. com/). Energy-
converting biochemical processes, primarily related to glucose and fatty acid (FA) metabolism, 
were distinguished as KMT2D-mediated cellular functions (figure 3H). Collectively, both the 
ChIP-seq and microarray studies point to the association of KMT2D expression with 
metabolism-related pathways.  
To further explore the functional consequences of the metabolism-associated KMT2D 
target(s), we measured changes of nicotinamide adenine dinucleotide phosphate (NADPH), 
which represents a fundamental common mediator of various biological processes including 
energy metabolism.11 We found that cells harbouring low KMT2D levels accumulate higher 
NADPH levels in comparison with control cells (supplementary figure S6A). Given this 
observation, we reasoned to assay cultured cells in real time using an XF24-3 Analyzer to 
query changes in the bioenergetic status of KMT2D-suppressed versus control pancreatic 
cancer cells. Simultaneous assessment of both oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) in basal state showed enhanced relative contribution of 
glycolysis on KMT2D suppression (figure 3I and online supplementary figure S6B, C). In 
particular, significant increase in ECAR values was observed, while OCR seems to remain 
unaffected, thus augmenting cellular preference for aerobic glycolysis. By quantifying the 
activity of the two major energy-yielding pathways in the cell, mitochondrial respiration and 
glycolysis, we provide evidence of a clear discrimination in the metabolic profiles driven by 
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loss of KMT2D expression. Furthermore, lactate production as well as glucose uptake were 
found to be significantly elevated on KMT2D silencing (online supplementary figure S6D–G). 
In light of the above results, we hypothesised that KMT2D could influence glucose metabolism 
by controlling key glycolytic genes. Expression of the SLC2A1 (glucose transporter-1 (GLUT-
1) that typically correlates with the rate of cellular glucose metabolism was found to be merely 
upregulated (+1.25-fold change) in KMT2D-silenced cells (figure 4A) and was not significantly 
affected in the tumors originating from xenografts bearing KMT2D stably suppressed 
pancreatic cancer cells (supplementary figure S7). Of note, solute carrier family 2 member 3 
(SLC2A3) (also known as GLUT3) was distinguished as the top differentially expressed 
glycolysis-related gene on KMT2D downregulation (figure 4A–C and online supplementary 
figure S8). To rule out secondary effects related to the genetic status of SLC2A3 in the two 
different pancreatic cancer cell lines, we demonstrate that mostly common single nucleotide 
changes of SLC2A3 gene are observed, all of them ensuing synonymous substitutions (online 
supplementary table S8). Mapped DNA sequence reads from the ChIP-seq experiments 
mentioned above do not support the role of SLC2A3 as a direct KMT2D transcriptional target. 
Hence, we assessed whether KMT2D transcriptionally regulates SLC2A3 through an indirect 
effect. 
Tuberous sclerosis 1 (TSC 1), which acts as upstream negative regulator of mechanistic target 
of rapamycin (mTOR) activation, 12 was found to be significantly downregulated based on the 
gene expression array employed in KMT2D-supressed cells (figure 3G). In addition, by 
pharmacological or genetic strategies, it has been demonstrated that rapamycin-sensitive 
mTOR complex 1, consisting of mTOR itself and the regulatory-associated protein of mTOR 
(Raptor), is involved in the regulation of SLC2A3 expression. Specifically, loss of the TSC1 
induced mTOR hyperactivation and SLC2A3 overexpression through the activation of the IκB 
kinase/nuclear factor kappa-light chain- enhancer of activated B cells (IKK/NF-κB) pathway.13 
In another report, stimulation of NF-κB activity has also been shown to directly upregulate 
SLC2A3 gene transcription in mouse and human cells.14 Indeed, IB analysis shows that 
reduction of KMT2D expression leads to increased phosphorylation and thus activation of 
mTOR (figure 4D) and increased phosphorylation of NF-κB p65 in Ser 536 (figure 4E). On the 
other hand, the expression of REL-associated protein (p65) involved in NF-κB heterodimer 
formation, nuclear translocation and activation is not influenced on KMT2D genetic 
manipulation (supplementary figure S9). Silencing of mTOR, but not Rictor (a specific 
component of mTORC2), as well as rapamycin treatment, reverse the SLC2A3 upregulation 
that is induced by low KMT2D levels (figure 4F and online supplementary figure S10). 
Furthermore, the use of inhibitors of NF-κB activation resulted in the partial reversal of SLC2A3 
mRNA levels induction caused by KMT2D silencing (figure 4G). These data suggest that 
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KMT2D suppression promotes SLC2A3 expression via activation of the mTOR/NF-kB axis. 
The immunostaining patterns of activated NF-κB p65 and SLC2A3 in tumors from xenografts 
bearing KMT2D stably suppressed or mock-transfected MIA PaCa-2 cells (online 
supplementary figure S11) validated our in vitro findings. Most importantly, treatment of 
pancreatic cancer cells with siRNA for SLC2A3 rescues the metabolic (figure 4H), proliferative 
(figure 4I and online supplementary tables S9–S10) and anchorage-independent growth 
phenotypes (figure 4J) that are associated with KMT2D suppression. Collectively, the 
functional features displayed by SLC2A3 reduction in KMT2D low-expressing cells highlight 
its role as a mediator of KMT2D-induced effects. 
Polyunsaturated fatty acids are increased in KMT2Dsuppressed cells and promote cell 
growth time-dependently. 
It is now considered that cancer cells support their increased growth rate by increasing either 
the uptake of exogenous lipids or their endogenous synthesis.15 Functional enrichment 
analysis (figure 5A), as well as bioinformatics prediction of the top-rated pathways and 
networks (figure 3G and supplementary table S11) of differentially expressed genes in 
KMT2D-silenced cells, suggest that KMT2D expression has an impact on lipid metabolic 
processes. Genes found in the functional cluster are illustrated in figure 5B, and among those, 
fatty acid synthase (FASN), which encodes a multienzyme protein catalysing FA synthesis, is 
one of the top differentially regulated genes on KMT2D downregulation (supplementary figure 
S12). Interestingly, we noticed that MIA PaCa-2 and CAPAN-2 bearing xenografts exhibit a 
clear trend of increased body weight, mainly at prolonged stages of tumour growth (figure 5C 
and online supplementary figure S13), even though these mice were possibly expected to be 
of poorer health given their increased tumor burden. However, the increase in the overall body 
weight of the mice most possibly relates to the increased weight of the tumours.  
As a next step, we used mass spectrometry-based technology to assess quantitative changes 
in FA composition and cholesterol content as a response to KMT2D silencing. Specifically, the 
total number of lipid species identified accounts for 28 FAs, all of which displayed increased 
levels relative to control cells (Table 1), with the most prominent differences being observed 
for the polyunsaturated fatty acids (PUFAs) docosadienoic, docosatrienoic and 
docosatetraenoic (Table 1 and figure 5D).  
Interestingly, addition of the aforementioned lipids in serum free conditions resulted in 
increased MIA PaCa-2 cell growth in a time-dependent and dose-dependent manner (figure 
5E) but did not affect pancreatic cancer cell’s invasive capacity (supplementary figure S14). 
Furthermore, elevated cholesterol uptake was detected in MIA PaCa-2 cultured cells 
transiently transfected with an siRNA against KMT2D, as assessed by fluorescence 
microscopy (figure 5F). Subsequently, we explored whether cells harbouring low or high 
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KMT2D levels differentially respond to perturbations in lipid homeostasis by (1) silencing the 
low-density lipoprotein receptor (LDLR), the main selective route of cholesterol-rich lipoprotein 
entrance into cancer cells; (2) blocking the ATP citrate lyase, a critical enzyme for de novo 
synthesis of a wide range of complex cellular lipids such as cholesterol and long-chain FAs 
using the SB 204990 inhibitor; and (c) blocking the Δ6 desaturase, the rate-limiting enzyme 
that initiates the metabolism of the n-6 and n-3 PUFAs, linoleic acid and α-linolenic acid, 
respectively, into their downstream long-chain FA conversion products using the selective SC 
26196 inhibitor. We found that reduction in MIA PaCa-2 cell proliferation rate caused by lipid 
synthesis/ uptake blockage is more pronounced in cells lacking KMT2D expression, with the 
maximum effect among the compounds used being observed in the case of the selective Δ6 
desaturase inhibitor SC 26196 (figure 5G). The latter result substantiates the functional 
importance of the top KMT2D-regulated lipids in pancreatic cancer, since the SC26196 
compound inhibits the rate-limiting step in arachidonic acid synthesis pathway, in which both 
docosadienoic and docosatetraenoic acids are implicated. Overall, these results revealed that 
the cellular lipid profiles depend on KMT2D expression. Furthermore, we are the first ones to 
show the potential of docosadienoic, docosatrienoic and docosatetraenoic acids to promote 
growth of pancreatic cancer cells, as evidenced by time-dependent studies. 
Synergistic role of glycolytic and lipidomic effectors in KMT2D-related phenotype. 
Lipogenic phenotype (characterised by increased FA synthesis, lipids’ uptake and 
metabolism) has been functionally and temporally linked to the glycolytic metabolism in 
primary and metastatic cancers as essential interaction regulating the malignant phenotype.16 
Thus, we explored whether KMT2D-mediated impact on cancer cell proliferation is 
interdependent on both glucose/lipid metabolism-related downstream effectors. Notably, 
combined treatment of cells with an siRNA for SLC2A3 and the SC26196 inhibitor completely 
reversed the effect of KMT2D depletion in MIA PaCa-2 cell proliferation (figure 5H), thus 
indicating the synergistic role of both SLC2A3 expression and maintenance of proper lipid 
composition as mediators of KMT2D-induced proliferative phenotype. 
Clinical relevance of the KMT2D expression in pancreatic cancer. 
To define the clinical relevance of our findings, KMT2D expression was examined by IHC and 
quantitative automated image analysis in matched adjacent control-cancerous tissues from 26 
patients with pancreatic cancer (cohort IV). KMT2D staining patterns showed that its nuclear 
localisation is almost absent in tumour samples, while highly expressed in normal tissues 
(Figure 6A and supplementary figure S15A). Further analysis of KMT2D expression in 
subgroups reflecting stage I or II of patients with pancreatic cancer (cohort IV), shows that the 
decrease in KMT2D levels may be significant in advanced stages of the disease 
(supplementary figure S15B). However, whether KMT2D levels relate to disease progression 
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needs to be further explored in extended numbers of human biopsies and genetically 
engineered mouse models of pancreatic cancer. Kaplan-Meier analysis performed in 158 
cases (cohort V) and in 22 cases (cohort III) revealed that patients with pancreatic cancer 
harbouring low KMT2D expression levels had worse prognosis in comparison with patients 
harbouring high KMT2D levels (figure 6B and online supplementary figure S16). Sample 
power calculations conducted for the larger cohort V suggest that an extended sample size 
(over 2800 cases) is needed to reach statistical significance supplementary table S12). It 
should be highlighted that the samples derived from cohort V reflect mostly (90%) stage II 
cases, thus rendering it very difficult to detect survival differences with statistical significance. 
On the other hand, 86% of the tumours derived from cohort III reflect patients with stage III 
pancreatic cancer. Subsequently, we conducted correlation analysis for the levels of KMT2D 
with its downstream effectors. Expectedly, the Pearson coefficients computed reflect a 
negative correlation between KMT2D and SLC2A3 mRNA levels (figure 6C, D), based on 
publicly available gene expression array data and our experimental RT-qPCR validation 
studies. Significantly, IHC analysis of activated NF-κB p65 and SLC2A3 in matched adjacent 
control-cancerous tissues shows increased immunostaining of both in the tumor-derived 
samples where KMT2D protein levels were found to be very low compared with normal 
samples. These results further validate our in vitro mechanistic findings that suggest KMT2D-
dependent NF-kB activation and thus SLC2A3 upregulation in pancreatic cancer. 
Correlation of KMT2D expression with various clinical parameters is illustrated in table 2 and 
supplementary table S13. No significant association was observed between KMT2D 
expression and age (p=0.4976), sex (p=0.2999) or race (p=0.3702). Interestingly, patients with 
high KMT2D levels display dramatic weight loss and higher BMI values with high statistical 
significance. Out of 106 cases with above median (>3.917) KMT2D expression, 84 (79.2%) 
cases lost an average of 9.366 kg (20.65 pounds). On the other hand, a significant correlation 
of KMT2D expression was further observed in 95 cases with increased body fat, as assessed 
by BMI measurements. In our attempt to address whether biopsies derived from patients 
harbouring low KMT2D levels exert quantitative changes in FA composition and cholesterol 
content relatively to control tissues, we performed lipidomics analysis in samples derived from 
cohort II. Remarkably, we found that among the top lipids being robustly upregulated with 
statistical significance in human biopsies are docosadienoic, docosatrienoic and 
docosatetraenoic acids, thus validating our in vitro results showing dramatic increase of these 
PUFAs on genetic inactivation of KMT2D in pancreatic cancer cells (Table 3). Overall, these 
findings support the relevance of KMT2D for human pancreatic carcinogenesis. Figure 7 
shows a diagram illustrating the upstream and downstream effectors of KMT2D expression 




Novel role for the KMT2D-H3K4me axis in pancreatic cancer. 
Studies illustrating the role of KMT2D in histone H3K4 methylation at enhancers17 or in the 
maintenance of genome stability in genes18 help rationalize its widespread role in 
tumorigenesis. Based on a somatic knockout of KMT2D in human cells, microarray analysis 
revealed that a subset of genes that were associated with KMT2D-enriched loci displayed 
reduced expression in KMT2D-depleted cell lines that was accompanied by reduced 
H3K4me3.19 Recent research focus indicates the direct connections between metabolism and 
chromatin dynamics, underlying many aspects of metabolic dysfunction. Interestingly, 
KMT2D-activating signal cointegrator-2 complex has been shown to play redundant but 
essential roles in ligand-dependent H3K4me3 and expression of liver X receptor target 
genes20 and peroxisome proliferator-activated receptor gamma-dependent adipogenesis21 
and hepatic steatosis.22 
Here, by analysing pathways derived from H3K4me3 regions, we identified an association of 
KMT2D expression with metabolic processes. Our ChIP-seq data and mechanistic 
experiments support that STK11 represents a direct regulatory target of KMT2D. Noteworthy, 
several groups suggest that STK11 role as a master regulator of polarity and metabolism 
contributes to its tumor suppressor function.23 24 Beyond that, our ChIP-Seq data show that 
several transcription factors’ loci exhibit significantly reduced H3K4me3 occupancy in KMT2D-
silenced cells. Interestingly, it has been reported that focal rather than global loss of the 
H3K4me1/me2 marks has been observed at putative enhancers in mouse KMT2D-depleted 
lymphomas, and among the genes with concurrent expression changes were tumor 
suppressor genes.25 In the present study, we did not explore H3K4me1 and H3K4me2 
abundance on KMT2D silencing, since global loss of the marks genome-wide was not 
observed in pancreatic cancer cells. However, the possibility of H3K4me1/ me2 enrichment 
loss on KMT2D silencing in a focal manner could not be excluded. These data point to the 
complexity of a gene network contributing to the KMT2D-related metabolic phenotype of 
pancreatic cancer cells, either by the direct action of metabolic genes and/or by the secondary 
effects induced by transcription factors. 
Importance of SLC2A3 glucose transporter in pancreatic cancer. 
Many studies have reported oncogenic aberrations of key glycolytic enzymes that 
mechanistically stimulate activation of glucose uptake.26 SLC2A1 (GLUT-1) is a member of 
the GLUT family of facilitative glucose transporters that accounts for the uptake of glucose by 
malignant cells to a high extent. It is overexpressed in a wide range of human cancers, 
including pancreas,27 and forced overexpression of SLC2A1 has been shown to induce 
pancreatic cancer cellular invasiveness.28 However, in pancreatic cancer cells and xenografts 
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harbouring low KMT2D levels, minor changes in SLC2A1 levels were observed, while very 
significant alterations were found in SLC2A3 expression. We found induction of the SLC2A3 
glucose transporter triggered by KMT2D suppression, the former mediating the effect of 
KMT2D on cellular metabolism and proliferation. SLC2A3 displays a high affinity for glucose, 
thus ensuring efficient glucose uptake29; however, its expression is very low or undetectable 
in most organs of healthy adults. Of note, the impact of SLC2A3 levels on the stimulation of 
brain tumour initiating cells’ growth has been recently demonstrated,30 and pathological 
SLC2A3 overexpression has been reported in pancreatic cancer.31 In this realm, we now 
unveil a novel mechanism where the epigenome regulates the glycolytic profile of pancreatic 
cancer cells via SLC2A3 regulation. 
Disease relevance for KMT2D-regulated pathways. 
The biological findings reported in the literature suggest a cell type or context-dependent 
functional role of KMT2D in cancer. Impairment of cellular growth and invasion in breast 
cancer mouse xenografts, as well as in human colorectal and medulloblastoma cell lines, has 
been attributed to KMT2D knockdown. 32 33 On the other hand, Lee and colleagues34 showed 
that KMT2D interacts directly with p53 to promote expression of p53 target genes. Remarkably, 
its early loss has been shown to facilitate lymphomagenesis by remodelling the epigenetic 
landscape of the cancer precursor cells.35 Our study supports that KMT2D restrains 
pancreatic cancer growth through the regulation of metabolic pathways. However, the study 
of Dawkins et al36 focusing on the impact of H3K4 methyltransferases KMT2C and KMT2D in 
pancreatic adenocarcinoma biology points towards an oncogenic role for KMT2D. Specifically, 
transient knockdown of KMT2D in a panel of pancreatic cancer cell lines resulted in growth 
inhibition.36 In our study KMT2D expression was stably blocked by four different shRNA 
sequences, thus evaluating the long-term effects of KMT2D inhibition of expression. The latter 
provides confidence for the specificity of the KMT2D-induced functional effects. Moreover, we 
performed real-time cell proliferation analysis based on the application of electrical cell 
substrate impedance changes method, which exhibits many advantages over the conventional 
endpoint assays for monitoring cell proliferation. Beyond the differences in the technical set-
up, acquisition or loss of mutations by cancer cell lines could not be excluded. Nonetheless, 
the functional effects of KMT2D are supported by our mechanistic studies, showing that the 
genomic, glycolytic and lipidomic changes caused by KMT2D suppression refer and relate to 
a status of increased bioenergetic needs of proliferating cells. Furthermore, silencing of 
KMT2D causes significant alterations on the expression levels of genes with well-established 
roles in the biosynthesis, beta-oxidation, degradation or uptake facilitation of lipids, such as 
FASN, ACACA, LIPA and HMGCR. FASN, which was distinguished among the top 
differentially regulated genes on KMT2D downregulation, is essential for catalyzing the 
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formation of palmitate from acetyl-coenzyme A and malonyl-coenzyme A in the presence of 
NADPH, thus controlling the FAs biosynthesis.37 It is considered a viable candidate as 
indicator of pathological state, marker of neoplasia, as well as pharmacological treatment 
target in pancreatic cancer.38 39 In our in vitro experimental setting, FASN upregulation 
triggering increased FA synthesis possibly accounts for the moderate increase in palmitic acid 
levels, which is the first FA produced during FA synthesis and is the precursor to longer FAs. 
However, this finding was not validated in patients with pancreatic cancer (cohort III), as 
assessed by correlation analysis or KMT2D/FASN mRNA levels. This discrepancy could 
possibly be attributed to the small sample size used, which may not be adequate to detect 
significant correlations and/or the diversity of the genetic/ epigenetic patterns and other 
features of human pancreatic tumours. Nonetheless since a broader network of lipid-related 
genes are affected in KMT2D-suppressed pancreatic cancer cells, the extent to which distinct 
pathways such as lipid synthesis/ degradation/metabolism or efflux contribute to the 
phenotype of altered lipid profiles is currently under further investigation.  
Interestingly, by using adipogenesis as a synchronised model of cell differentiation, it has been 
previously indicated that KMT2D exhibits cell type-specific and differentiation stage-specific 
genomic binding and is predominantly localised on enhancers. These data suggest a stepwise 
model of enhancer activation during adipogenesis that includes cooperative recruitment of 
KMT2D to perform H3K4me1/2 on enhancer-like regions by lineage-determining transcription 
factors, such as C/EBPβ, PPARγ and C/ EBPα.17 In accordance to the concept of KMT2D as 
a component of genetic regulation that affects adipose/lipid homeostasis, our human data 
point out that patients harbouring high KMT2D expression experience greater weight loss and 
higher BMI than patients whose KMT2D levels are below the median value. The sample size 
of cohort V did not have enough power to define survival differences; however, there was a 
trend of increased survival in patients with higher levels of KMT2D. Discordance with the study 
of Dawkins et al,36 showing that reduced expression of KMT2D correlates with improved 
outcome in PDAC, most possibly arises due to sample type differences, especially given that 
cohort V consists of samples from resected (stage II) cases. It has been documented that not 
only the degree of weight loss impacts survival of patients with pancreatic cancer, but also the 
proportion of muscle and fat loss in the different compartments.40 Fat oxidation, decreased 
lipogenesis, impaired lipid deposition/adipogenesis and mainly elevated lipolysis have been 
linked to fat loss; however, the underlying mechanisms have not been clearly defined.41 It is 
tempting to speculate that KMT2D expression may account for body weight and composition 
changes during illness progression, as a factor causing alterations in glucose/lipid/metabolism. 
Taken together, our experimental strategy has revealed the mechanisms that regulate KMT2D 
expression and its downstream effectors in pancreatic oncogenesis. The present study offers 
16 
 
significant mechanistic value for potential treatment of pancreatic cancer as a metabolic 
disease regulated by the epigenome. 
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Figure 1: Histone methyltransferase KMT2D acts as a tumour suppressor in pancreatic 
cancer. (A) KMT2D mRNA expression levels in three cohorts of pancreatic cancer and normal 
tissues, as assessed by RT-qPCR. (B) Transient suppression of KMT2D expression by two 
different siRNAs in pancreatic cancer cells. Efficiency of KMT2D downregulation, as assessed 
by RT-qPCR (left panel) and by IB analysis (right panel). Whole cell protein extracts were 
analysed by IB analysis for total KMT2D or CREB (used as a loading control). Numbers in 
parentheses denote the average fold change of the KMT2D:CREB total protein ratio of 
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siKMT2D transiently transfected cells compared with siC#1-treated cells (set as default 1) of 
at least two independent experiments, as assessed by densitometric analysis of the 
immunoreactive bands. (C) Dynamic monitoring of cellular proliferation on KMT2D transient 
suppression by using siKMT2D#2, using the xCELLigence RTCA SP system. (D) Assessment 
of KMT2D expression levels in MIA PaCa-2 cells transfected with #2–21 shRNA against 
KMT2D that underwent clonal selection resulting in clones a, b and c, by RT-qPCR (left panel) 
and IB analysis (right panel). Numbers in parentheses denote the average fold change of the 
KMT2D:CREB total protein ratio of shKMT2D stably transfected cells compared with mock-
treated cells (set as default 1), as assessed by densitometric analysis of the immunoreactive 
bands. (E) Dynamic monitoring of the proliferation of the shKMT2D#2-21a clonal pancreatic 
cancer cell lines versus mock-transfected cells. (F) Effect of KMT2D stable suppression on 
soft agar colony formation. (G) Representative images of the excised tumours and (H) tumour 
volume (mm3) graphs of xenografts bearing KMT2D stably suppressed MIA PaCa-2 and 
CAPAN-2 cells (n=5 mice per group). For establishing shKMT2D#2-21a xenografts, MIA 
PaCa-2 or CAPAN-2 cells were injected subcutaneously in the right flank of NOD-SCID mice 
(five mice/group). (I) Representative IHC images for the proliferation marker Ki-67, 
corresponding to MIA PaCa-2 (upper two rows) and CAPAN-2 (bottom two rows) xenografts 
from mice injected with mock or shKMT2D#2-21a cells. Scale bars represent 50 μm. siC#1, 
cells transfected with a negative control scramble siRNA; siKMT2D#1, cells transfected with 
siRNA#1 for KMT2D; siKMT2D#2, cells transfected with siRNA#2 for KMT2D; mock, cells 
transfected with shRNA empty vector; shKMT2D#2–21, cells transfected with #2–21 shRNA 
for KMT2D; shKMT2D#2-21a, b or c, cells transfected with #2–21 shRNA for KMT2D that 
underwent clonal selection resulting in clones a, b and c; MX, mouse xenograft. OD, optical 
density. Statistical analyses were performed using one-way analysis of variance. Asterisks 
denote statistically significant differences, *p<0.05, **p<0.01, ***p<0.001. IB, immunoblot; IHC, 
immunohistochemical; KMT2D, histone lysine (K)-specific methyltransferase 2D; RT-qPCR, 
reverse transcription quantitative PCR; shRNA, short hairpin RNA; siRNA, small interfering 
RNA. 
Figure 2: Epigenetic regulation of KMT2D levels through DNA methylation of two CpG 
sites. (A) Experimental design for the evaluation of KMT2D transcriptional repression-
dependency on CpG methylation in pancreatic cancer. (B) Heatmap of methylation beta 
values for the selected probes (p<0.05, mean difference ≥0.25). Wilcoxon rank-sum tests were 
conducted to compare methylation array data between patients with pancreatic cancer and 
healthy controls. (C) Validation of CpG methylation levels via targeted bisulfite sequencing for 
the selected ROI (chr12: 49448986–49449286). Quantitative methylation measurements at 
the single CpG site level for untreated or 5-AZA-CdR-treated cells are box plotted (left panel) 
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or depicted as heatmaps of the methylation ratio (right panel). The colour indicates the level 
of methylation from higher to lower in yellow > orange> red order. (D) Dose response 
evaluation of 5-AZA-CdR treatment for 48 hours in KMT2D mRNA levels, as assessed by RT-
qPCR. (E) Effect of 5-AZACdR treatment for 48 hours on KMT2D protein levels, as assessed 
by IB analysis. Numbers in parentheses denote the average fold change of the KMT2D:CREB 
total protein ratio in 5-AZA-CdR-treated cells compared with 0.005% DMSO-treated cells (set 
as default 1). (F) Schematic depiction of the distinct KMT2D/hRluc constructs used; the 
engineered hRluc was coupled to the genomic region (positions −179 to +121) of the human 
KMT2D gene. Tick marks represent the number and location of CpG dinucleotides. (G) The 
efficiency of CpG methylation was assessed in unmethylated and methylated, linearized and 
gel-purified constructs by resistance to digestion with HpaII endonuclease and subsequently 
agarose gel analysis. (H, I) Relative hRluc activity after in vitro methylation of KMT2D 
constructs using the promoterless pGL4.82 (hRluc/Puro) vector gene system. HRluc mean 
fluorescence intensity was measured in MIA PaCa-2 cells transfected with either (H) untreated 
or (I) CpG methyltransferase (MSssl)-treated KMT2D/hRluc constructs. To control for 
transfection efficiency, cells were co-transfected with a plasmid containing firefly luciferase 
(Luc) reporter gene and the levels of hRluc fluorescence were averaged over all Luc 
expressing cells. Statistical analyses were performed using one-way analysis of variance. 
Asterisks denote statistically significant differences, *p<0.05, **p<0.01, ***p<0.001. 5-AZA-
CdR, 5-AZA-2'-deoxycytidine; DMSO, dimethyl sulfoxide; IB, immunoblot; KMT2D, histone 
lysine (K)-specific methyltransferase 2D; ROI, region of interest; RT-qPCR, quantitative 
reverse transcription PCR. 
Figure 3: KMT2D-regulated pancreatic cancer cells’ transcriptome and epigenome. (A) 
Effects of KMT2D silencing on the global levels of histone H3K4 monomethylation, 
dimethylation and trimethylation using IB analysis. Numbers in parentheses denote the 
average fold change of the H3K4me1, H3K4me2 or H3K4me3:H3 total protein ratio in KMT2D-
silenced cells versus siC#1-treated cells (set as default 1). (B) Enrichment scores comparing 
the read density conditions for each set of peak regions are shown in the jittered boxplots. The 
enrichment values were tested with the Mann-Whitney U test (p<0.001). (C) Overlap of 
H3K4me3 peaks on KMT2D suppression using two different siRNAs. (D) Effect of KMT2D 
silencing on the genomic distribution of H3K4me3 peaks in MIA PaCa-2 cells. Pie chart 
indicates the enriched H3K4me3 peaks in negative siRNA versus siKMT2D#2-treated cells. 
(E) Distribution of H3K4 trimethylation mark around TSS. (F) GO terms associated with 
H3K4me3 binding sites were determined as follows: ChIP-seq peaks found in siC#1-treated 
cells versus peaks found in cells treated with siKMT2D#2 were associated with the nearest 
ENSEMBL transcript and processed using the DAVID (V.6.7) tool. The data presented are 
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log-transformed p value of GO terms found to be enriched in the tested group of genes. (G) 
Heatmap showing the differentially expressed genes in MIA PaCa-2 cells on KMT2D 
suppression. Data were filtered using a p value cut-off of 0.05 and a fold change cut-off of 2.0. 
Clustering dendrograms show the relative expression values according to the following 
colouring scheme: red: high; black: moderate; green: low. (H) List of metabolism-associated 
canonical pathways derived from the IPA GO algorithms for the KMT2D-regulated genes (from 
figure 3G). −log (p value) is measured by the bar length, while R refers to the number of 
molecules from the data set that map to the pathway listed divided by the total number of 
molecules that map to the pathway from within the IPA knowledge base. (I) OCR/ECAR curves 
for KMT2D stably transfected pancreatic cancer cells (Seahorse Technology). R, ratio; oligo, 
oligomycin; FCCP, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone; RM, 
rotenone/myxothiazol. ChIP-seq, chromatin immunoprecipitation-sequencing; ECAR, 
extracellular acidification rate; GO, Gene Ontology; IB, immunoblot; IPA, Ingenuity Pathway 
Analysis; KMT2D, histone lysine (K)-specific methyltransferase 2D; OCR, oxygen 
consumption rate; siC#1, cells transfected with a negative control scramble siRNA; 
siKMT2D#1, cells transfected with siRNA#1 for KMT2D; siKMT2D#2, cells transfected with 
siRNA#2 for KMT2D; siRNA, small interfering RNA; TSS, transcription start site. 
Figure 4: KMT2D regulates pancreatic cancer cell growth and metabolism by affecting 
SLC2A3 glucose transporter. (A) Heatmap summarising the differentially expressed 
glycolysis-related genes in MIA PaCa-2 cells on KMT2D suppression. Data were filtered using 
a p value cut-off of 0.05 and a fold change cut-off of 1.25. (B) SLC2A3 mRNA expression in 
pancreatic cancer cells on KMT2D silencing. (C) SLC2A3 expression in MIA PaCa-2 
xenografts from mice injected with mock or shKMT2D#2-21a cells, as assessed by RT-qPCR. 
(D) Representative IB images for the activated and total (D) mTOR and (E) NF-κB p65 on 
KMT2D silencing. Numbers in parentheses denote the average fold change of the 
phosphorylated:total protein ratio of KMT2D-silenced cells versus siC#1-treated cells (set as 
default 1) of at least two independent experiments. (F) Representative IB images for SLC2A3, 
mTOR, Rictor and CREB protein levels on treatment of MIA PacA-2 cells harbouring 
differential KMT2D levels with siRNAs against mTOR, Rictor or the respective scramble 
control. Numbers in parentheses denote the average fold change of the SLC2A3:CREB total 
protein ratio of siRNAtreated cells versus siC#1-treated cells (set as default 1). (G) Treatment 
of MIA PaCa-2 cells with inhibitors of NF-κB activation for 24 hours reverses the KMT2D-
mediated increase in SLC2A3 mRNA levels. Effects of SLC2A3 silencing on the (H) 
bioenergetic status, (I) proliferation and (J) colony formation ability of KMT2D-suppressed 
cells. Statistical analyses were performed using one-way analysis of variance. Asterisks 
denote statistically significant differences, *p<0.05, **p<0.01, ***p<0.001. DMSO, dimethyl 
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sulfoxide; ECAR, extracellular acidification rate; FCCP, carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone; IB, immunoblot; KMT2D, histone lysine (K)-specific methyltransferase 2D; 
mechanistic target of rapamycin (mTOR);NF-κB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; OCR, oxygen consumption rate; OD, optical density; oligo, oligomycin; RM, 
rotenone/myxothiazol; RT-qPCR, reverse transcription quantitative PCR;siRNA; small 
interfering RNA; siC#1, cells transfected with a negative control scramble siRNA; siKMT2D#1, 
cells transfected with siRNA#1 for KMT2D; siKMT2D#2, cells transfected with siRNA#2 for 
KMT2D; siSLC2A3, cells transfected with siRNA for SLC2A3. 
Figure 5: KMT2D inhibition alters the lipid composition and cholesterol content in 
pancreatic cancer. (A) GO-based annotation was used to perform functional enrichment 
analysis using the DAVID (V.6.7) tool. Fold enrichment of genes (associated with lipid 
metabolic processes) regulated by KMT2D levels is measured by the bar length while p value 
represents the significance of the enrichment. (B) Heatmap summarising the differentially 
expressed lipid metabolism-related genes in MIA PaCa-2 cells on KMT2D suppression. Data 
were filtered using a p value cut-off of 0.05 and a fold change cut-off of 1.5. (C) Body weight 
graphs of mouse xenografts bearing MIA PaCa-2 or CAPAN-2 shKMT2D#2-21a clonal cell 
lines and mock transfected cells (n=5 mice per group). (D) Column graph illustrating 
quantitative changes of the top 3 FAs regulated by KMT2D. (E) Time-dependent and dose-
dependent effects of exogenously added FAs on cell proliferation, as assessed by CellTiter 
Glo Luminescence Cell Viability Assay. (F) Detection of cholesterol uptake within MIA PaCa-
2 cultured cells, as assessed by fluorescence microscopy. Scale bars represent 50 μm. (G, 
H) Time-dependent effect of LDLR or SLC2A3 silencing, SC 26196 and SC 204990 inhibitors 
on cell proliferation in high and low KMT2D-expressing cells, as assessed by CellTiter Glo 
Luminescence Cell Viability Assay. Statistical analyses were performed using one-way 
analysis of variance. Asterisks denote statistically significant differences, *p<0.05, **p<0.01, 
***p<0.001. FA, fatty acid; FBS, fetal bovine serum; GO, Gene Ontology; KMT2D, histone 
lysine (K)-specific methyltransferase 2D; LDLR, low-density lipoprotein receptor. 
Figure 6: Correlation of KMT2D levels between its targets and disease aggressiveness. 
(A) (i) Representative images (10× magnification) of KMT2D expression, as assessed by IHC 
analysis, in matched cancer and normal tissues from patients with pancreatic cancer (cohort 
IV). (ii) Automated image analysis using the Spectrum Software V.11.1.2.752 (Aperio) was 
performed for nuclear staining quantification. (B) Correlation of KMT2D expression with overall 
patient survival. Kaplan-Meier survival curves of patients harbouring below median (<3.917) 
and above median (>3.917) KMT2D levels derived from cohort V. (C, D) Correlation of KMT2D 
levels with SLC2A3 expression in patients with pancreatic cancer based on the study by 
Badea et al4 and as assessed by RT-qPCR (cohort III). (E) Representative images (10× 
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magnification) of phospho-NF-kB p65 (Ser 536) and SLC2A3 expression, as assessed by IHC 
analysis, in matched cancer and normal tissues from patients with pancreatic cancer (cohort 
IV). Scale bars represent 50 μm. r, Pearson correlation coefficient; Kaplan-Meier test was 
used for univariate survival analysis. Cox proportional hazard model was used for multivariate 
analysis and for determining the 95% CI. Statistical analyses were performed using one-way 
analysis of variance or Pearson correlation. Asterisks denote statistically significant 
differences, **p<0.01. BMI, body mass index; IHC, immunohistochemical; KMT2D, histone 
lysine (K)-specific methyltransferase 2D; NF-kB, nuclear factor kappa-light-chain-enhancer of 
activated B cells; RT-qPCR, reverse transcription quantitative PCR. 
Figure 7: Schematic depiction of KMT2D transcriptional regulation and downstream 
mechanistic targets and pathways in pancreatic cancer. Methylation of two single CpG 
sites transcriptionally represses KMT2D histone methyltransferase expression. Suppression 
of KMT2D induces aerobic glycolysis and lipid levels in pancreatic cancer. SLC2A3 consists 
a key mediator of the cellular growth and metabolic effects triggered by KMT2D 
downregulation. Docosadienoic, docosatrienoic and docosatetraenoic acid represent the top 
KMT2D-regulated fatty acids and harbour oncogenic properties in pancreatic cancer cells. 
KMT2D, histone lysine (K)-specific methyltransferase 2D. 
 
TABLE LEGENDS 
Table 1: Quantitative LC-MS data of fatty acids and total cholesterol in MIA PaCa-2 cells 
pretreated with siC#1 or siKMT2D#2. The top three lipids most significantly elevated by 
KMT2D reduction are shown in bold. Statistical analyses were performed using one-way 
analysis of variance. KMT2D, histone lysine (K)-specific methyltransferase 2D. 
Table 2: Pancreatic carcinomas were subdivided into two groups: carcinomas with below 
median (<3.917) KMT2D expression and carcinomas with above median (>3.917) KMT2D 
expression. n is the number of patients with clinical information. Clinical correlations were 
examined using the SAS 9.4 for LINUX platform. BMI, body mass index; KMT2D, histone 
lysine (K)-specific methyltransferase 2D; LC-MS, Liquid Chromatography-Mass Spectrometry. 
Table 3: Quantitative LC-MS data of fatty acids and total cholesterol in pancreatic cancer 
biopsies versus normal tissues. Pancreatic carcinomas from cohort II were subdivided into 
two groups: carcinomas with below median (<0.3) KMT2D expression and carcinomas with 
above median (>0.3) KMT2D expression. Four cancerous tissues displaying below median 
(<0.3) KMT2D levels underwent lipidomic profiling. The top three lipids most significantly 
elevated are shown in bold. Statistical analyses were performed using one-way analysis of 
variance.∞ represents infinity as the denominator is so small that is virtually zero; KMT2D, 
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  Percentage  
change 
P values 
Docosatrienoic acid 0.6 1.5 +150 0.00482 
Docosadienoic acid 0.35 1 +186 0.00971 
Docosatetraenoic acid 1.425 3.5 +150 0.01084 
Nervonic acid  4.1  10.1 +146.3 0.00217 
Eicosadienoic acid   2.825 6.55 +131.8 0.00557 
Dihomo-g-linolenic acid 1.3 2.925 +125 0.0075 
Eicosapentaenoic acid 8 17.075 +113.4 0.19345 
Eicosenoic acid 32.675 68.675 +110.2 0.00116 
Docosapentaenoic acid 
(n=3) 
4.55    9.1 +100 0. 0 00 229 
Docosenoic acid 3.65 6.825 +87 0.00364 
Docosahexaenoic acid 4.675   8.2  +75.4 0.02643 
Arachidonic acid 8.933 13.825  +54.8 0.009 
g-Linolenic acid 8.325 12.175   +46.2 0.16032 
Oleic acid          715.6 1049.775   +46.7 0.01402 
a-Linolenic acid 4.1   5.9   +43.9 0.16846 
Stearic acid           2563.2   3667.875   +43.1 0.11082 
Linoleic acid         23.7 33.575   +41.7 0.07341 
Hexacosanoic acid            7.05 9.95   +41.1 0.13026 
   Cholesterol   359.25 474.75   +32.2 0.04811 
Dodecanoic acid         82.25      108.1    +31.4 0.0013 
Palmitoleic acid 118.775 148.575    +25.1 0.26513 
Lignoceric acid 25.375 30.825    +21.5 0.21665 
Palmitic acid                 7676  8941.525    +16.5 0.05763 
Docosanoic (Behenic 
acid) 
9.575 10.475    +9.4 0.38668 
Heptadecenoic acid              71.55 78.075    +9.1 0.10477 
Pentadecanoic 486.375 524.125    +7.8 0.27158 
Heptadecanoic acid            91.15      96.85    +6.3 0.35989 
Arachidic acid            20.55      21.65    +5.4 0.5251 








Table 2: Correlation of KMT2D expression with demographic and clinical characteristics of patients 
with pancreatic cancer (cohort V) 






Age at diagnosis   0.4976 
n 86 102  
Mean (SD) 64.65 (11.72) 64.01 (11.53)  
Median 66.50 63.50  
Q1, Q3 55.00, 75.00 57.00, 74.00  
Range (37.00–88.00) (41.00–92.00)  
Vital status   0.1274 
Missing 10 5  
Alive 14 (14.1%) 8 (7.5%)  
Deceased 85 (85.9%) 98 (92.5%)  
Survival (days) 
n 69 89  
Events 60 81  
Median survival days 712.0 (552.0–1017.0) 608.0 (518.0–811.0)  
5-year survival rate 11.7% (3.5%–20.0%) 19.7% (11.3%–28.2%)  
Year 5, n at risk 6 15  
Sex   0.2999 
Missing 10 5  
Female 52 (52.5%) 48 (45.3%)  
Male 47 (47.5%) 58 (54.7%)  
Race   0.3702 
Missing 14 5  
1=American Indian/Alaskan 
Native 
0 (0.0%) 1 (0.9%)  
2=Asian/Asian-American 2 (2.1%) 0 (0.0%)  
3=Black/African–American 1 (1.1%) 1 (0.9%)  
5=White 92 (96.8%) 104 (98.1%)  
Usual adult BMI   0.0040 
n 74 95  
Mean (SD) 27.31 (5.40) 29.92 (5.64)  
Median 27.01 29.19  
Q1, Q3 24.24, 30.04 25.75, 32.96  
Range (15.31–43.72) (18.88–46.18)  
Usual adult BMI (<30, 30+)   0.0367 
Missing 35 16  
<30 55 (74.3%) 56 (58.9%)  
30+ 19 (25.7%) 39 (41.1%)  
Weight loss   0.0005 
Missing 10 5  
No 43 (43.4%) 22 (20.8%)  
Yes 56 (56.6%) 84 (79.2%)  
Pounds lost   0.0001 
n 99 106  
Mean (SD) 5.116 (6.191) 9.3664 (8.323)  
Median 2.698 7.937  
Q1, Q3 0.00, 9.071 4.499, 13.607  
Range (0.00–27.215) (0.00–38.555)  
Stage at surgery   0.3117 
Missing 49 26  
IA 0 (0.0%) 1 (1.2%)  
IB 6 (10.0%) 6 (7.1%)  
IIA 12 (20.0%) 28 (32.9%)  
IIB 42 (70.0%) 49 (57.6%)  
IV 0 (0.0%) 1 (1.2%)  
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Docosatrienoic acid – 0.0125 ∞ 0.04006 
Docosadienoic acid – 0.0225 ∞ 0.02401 
Docosatetraenoic acid 0.0325 0.2125 +553.8 0.03181 
Nervonic acid 0.05 0.275 +450 0.07178 
Eicosadienoic acid 0.0475 0.6325 +1232 0.06733 
Dihomo-g-linolenic acid 0.075 0.34 +353 0.03279 
Eicosapentaenoic acid 0.085 0.1125    +32.35 0.64401 
Eicosenoic acid 1.0775 13.371 +1426.2 0.06179 
Docosapentaenoic acid (n=3) 0.045 0.2025  
+350 
0.08372 
Docosenoic acid 0.2375 1.34 +464.21 0.03204 
Docosahexaenoic acid 0.055 0.1625 +195.45 0.09208 
Arachidonic acid 0.695 1.32 +89.93 0.07636 
Oleic acid 36.4525 347.835 +854.2 0.13282 
a-Linolenic acid and g-
linolenic acid 
0.0225 0.315 +1300 0.05199 
Stearic acid 15.275 20.23 +32.94 0.59416 
Linoleic acid 3.1525 15.5675 +393.8 0.09712 
Hexacosanoic acid 0.0125 0.0225 +80.0 0.71105 
Cholesterol 23.28843 53.64114 +130.33 0.00787 
Dodecanoic acid 0.5075 1.87 +268 0.03587 
Palmitoleic acid 3.515 29.14 +788 0.09423 
Lignoceric acid 0.12 0.27 +125 0.29288 
Palmitic acid 25.89 59.3875 +129.4 0.17425 
Docosanoic (Behenic acid) 0.13 0.2725 +109.62 0.02932 
Heptadecenoic acid 0.4525 3.64 +704 0.10735 
Pentadecanoic 0.34 1.86 +447.1 0.06233 
Heptadecanoic acid 0.33 1.72 +421.2 0.06334 
Arachidic acid 0.14 0.5875 +319.64 0.02278 
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Supplementary Figure S1: Histone methyltransferase KMT2D acts as a tumor 
suppressor in pancreatic cancer. 
(A) Differential expression of chromatin regulators including KDM8, KDM4C, SETD6, 
SUV420H1, KDM2A, KDM5B and SETDB2 in pancreatic carcinoma versus normal 
tissues originating from Cohort II, as assessed by RT-qPCR. (B, C) Differential 
expression of Lysine (K)-Specific Methyltransferase 2D (KMT2D) in pancreatic 
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carcinoma versus normal tissues, based on 2 studies listed in Oncomine database [1 2]. 
(D, E) Relative mRNA levels of KMT2B and KMT2C in Cohorts II and III, as assessed 
by RT-qPCR. (F, G) Effect of transient KMT2D suppression by using siKMT2D#1 and 
the respective scramble control on pancreatic cancer cell proliferation, as assessed by 
the xCELLigence system. (H) Efficiency of KMT2D stable depletion by using 4 different 
shRNAs in MIA PaCa-2 cells, as assessed by RT-qPCR. (I-L) Effect of stable KMT2D 
suppression by using 4 different shRNAs on pancreatic cancer cell proliferation, as 
assessed by the xCELLigence system. (M, N) Assessment of the proliferative capacity 
of shKMT2D#2-21b clonal cell lines versus mock transfected cells. (O) Quantification of 
the colonies formed by shKMT2D#2-21 a and b clonal cell lines versus mock 
transfected cells. (P, Q) Tumor weight graphs of xenografts bearing KMT2D stably 
suppressed MIA PaCa-2 and CAPAN-2 cells (5 mice/group). KMT2D expression in MIA 
PaCa-2 and CAPAN-2 xenografts from mice injected with mock or shKMT2D#2-21a 
cells, as assessed by RT-qPCR (R) and IHC analysis (S). (T) Representative images of 
the excised tumors and (U) tumor volume (mm3) (V) and tumor weight graphs of 
xenografts from mice injected with mock or shKMT2D#2-21b cells. For establishing 
shKMT2D#2-21b xenografts, 3.5*106 MIA PaCa-2 and 4.5*106 CAPAN-2 cells were 
injected subcutaneously in the right flank of NOD-SCID mice (5 mice/group). siC#1, 
cells transfected with a negative control scramble siRNA; siKMT2D#1, cells transfected 
with siRNA#1 for KMT2D; mock, cells transfected with shRNA empty vector; 
shKMT2D#1-19, cells transfected with #1-19 shRNA for KMT2D; shKMT2D#1-21, cells 
transfected with #1-21 shRNA for KMT2D; shKMT2D#2-19, cells transfected with #2-19 
shRNA for KMT2D; shKMT2D#2-21, cells transfected with #2-21 shRNA for KMT2D; 
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shKMT2D#2-21a or b, cells transfected with #2-21 shRNA for KMT2D that underwent 
clonal selection resulting in clones a and b; MX, Mouse Xenograft. Statistical analyses 
were performed using one-way ANOVA. Asterisks denote statistically significant 




A       
 





























































Supplementary Figure S2. Epigenetic regulation of KMT2D levels through DNA 
methylation of two different CpG sites. 
(A) CpG methylation validation via Targeted Bisulfite Sequencing for the selected region 
of interest (ROI) (chr12: 49448986-49449286). Quantitative methylation measurements 
at the single-CpG-site level for untreated or 5-AZA-2'-deoxycytidine (5-AZA-CdR)-
treated BxPC-3, CAPAN-1 and CFPAC-1 cells are box plotted or depicted as heatmaps 
of the methylation ratio. The color indicates the level of methylation from higher to lower 
in yellow > orange > red order. (B) Dose response evaluation of 5-AZA-CdR treatment 
for 96 h of KMT2D mRNA levels, as assessed by RT-qPCR. Statistical analyses were 
performed using one-way ANOVA. Asterisks denote statistically significant differences, * 














Supplementary Figure S3: Assessment of the global H3K4me3 levels of control or 
KMT2D-silenced cells upon 5-AZA-CdR treatment. 
Effect of 5-AZA-CdR treatment for 48 h on the tri-methylated form of histone H3 at 
lysine 4 (H3K4me3) levels in control or KMT2D-silenced cells, as assessed by (A) 
Immunoblot (IB) analyses and (B) the quantification of the respective immunoreactive 
bands of 2 independent experiments. Statistical analyses were performed using one-
12 
 
way ANOVA. Asterisk denotes statistically significant differences, * P<0.05. (C) 
Numbers in parentheses denote the average-fold change of the ratio H3K4me1:CREB 
total protein (upper lane) and H3K4me2:CREB (lower lane) of 5-AZA-CdR-treated cells 





Supplementary Figure S4: ChIP-seq signals of H3K4me3 in KMT2D-silenced cells. 
Effects of KMT2D silencing measured by ChIP-seq on H3K4me3 occupancy of the 
General Transcription Factor IIA Subunit 1 (GTF2A1) genomic region. The enrichment 
values were tested with the Mann-Whitney U test (P<0.001). 
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Supplementary Figure S5: Evaluation of STK11 as a direct KMT2D transcriptional 
target. 
(A) Profiles of H3K4me3 ChIP-seq peaks at the Serine/Threonine Kinase 11 (STK11) 
locus upon KMT2D suppression. The x-axes indicate the genomic region. The y-axes 
represent the fold enrichment of H3K4me3 peaks compared with 2% input control. The 
14 
 
enrichment values were tested with the Mann-Whitney U test (P<0.001). (B) Luciferase 
activity mediated by STK11 promoter upon KMT2D silencing was evaluated 28 h after 
transfection of the STK11_pLightSwitch_ Prom Reporter or pLenti CMV Puro LUC 
vectors in MIAPaCa-2 cells. (C) STK11 mRNA levels in pancreatic cancer cell lines 
transiently-silenced of KMT2D, as assessed by RT-qPCR. Statistical analyses were 

























































































































































      



















































































































Supplementary Figure S6: KMT2D histone methyltransferase regulates pancreatic 
cancer cell metabolism. 
 (A) Endogenous nicotinamide adenine dinucleotide phosphate (NADPH) levels of MIA 
PaCa-2 cells pretreated with scramble siRNA or 2 different siRNAs against KMT2D, as 
assessed by the NADP/NADPH-Glo™ bioluminescent Assay. (B-C) Effects of KMT2D 
suppression, by using 2 different shKMT2D-stably transfected populations for each cell 
line on pancreatic cancer cells’ bioenergetic profile, as assessed by the XF24-3 
Analyzer. Effects of KMT2D silencing, by using 2 different siRNAs in (D and E) lactate 
production and (F and G) glucose uptake. Average basal OCR and ECAR were further 
normalized per protein for KMT2D stably-depleted cells. OCR, Oxygen Consumption 
Rate; ECAR, Extracellular Acidification Rate; 2-DG6P, the 2-deoxyglucose (2-DG) 
glucose analogue phosphorylated by hexokinase to 2-DG6P. Statistical analyses were 
19 
 
performed using one-way ANOVA. Asterisks denote statistically significant differences, * 






Supplementary Figure S7: Assessment of SLC2A1 mRNA levels in mouse 
xenografts. 
Solute Carrier Family 2 Member 1 (SLC2A1) expression levels in xenografts from mice 
injected with mock or shKMT2D#2-21a (i) MIA PaCa-2 or (ii) CAPAN-2 cells, as 





















































Supplementary Figure S8: Assessment of SLC2A3 mRNA levels and protein 
levels upon KMT2D genetic manipulation. 
(i) Solute Carrier Family 2 Member 3 (SLC2A3) expression levels in xenografts from 
mice injected with mock or shKMT2D#2-21a CAPAN-2 cells, as assessed by RT-qPCR 
analysis. (ii) Effect of KMT2D silencing by using 2 different siRNAs on SLC2A3 protein 
levels, as assessed by IB analysis. Numbers in parentheses denote the average-fold 
change of the ratio SLC2A3 : CREB total protein of siKMT2D-transiently transfected 
cells compared with siC#1-treated cells (set as default 1) of 2 independent experiments, 
as assessed by densitometric analysis of the immunoreactive bands. Statistical 
analyses were performed using one-way ANOVA. Asterisk denotes statistically 































Supplementary Figure S9: Assessment of REL-associated protein mRNA levels 
upon KMT2D genetic manipulation. 
Effect of KMT2D silencing on REL-associated protein (p65) expression, as assessed by 
RT-qPCR analysis. Statistical analyses were performed using one-way ANOVA. 
 
                                          
 
Supplementary Figure S10: Effect of pharmacological inhibition of mTORC1 on 
the SLC2A3 levels upon KMT2D suppression. 
Representative IB images for the indicated antibodies upon treatment of MIA PacA-2 


























parentheses denote the average-fold change of the ratio SLC2A3 : CREB total protein 


















Supplementary Figure S11: Phospho-NF-kB (Ser 536) and SLC2A3 staining 
patterns in mouse xenografts bearing KMT2D-depleted or mock-transfected 
pancreatic cancer cells. 
shKMT2D#2-21a 
mock 
XN:              #1                                  #2                                 #3                                 #4                                 #5 
phospho-NF-kb p65 (Ser 536) 
shKMT2D#2-21a 
mock 




Representative images (10x magnification) of (A) phospho-NF-kb p65 (Ser 536) and (B) 
SLC2A3 expression, as assessed by IHC analysis, in tumors from xenografts bearing 
KMT2D stably-suppressed or mock-transfected MIA PaCa-2 cells. Scale bars represent 
50 μm.  
Supplementary Figure S12: Assessment of FASN expression levels upon KMT2D 
suppression. 
(A) Fatty Acid Synthase (FASN) expression levels in KMT2D transiently-silenced 
pancreatic cancer cells, as assessed by RT-qPCR analysis. (B) FASN expression levels 
in KMT2D-transiently silenced pancreatic cancer cells, as assessed by IB analysis. (C) 
FASN mRNA levels in xenografts from mice injected with mock or shKMT2D#2-21a 
cells, as assessed by RT-qPCR analysis. Statistical analyses were performed using 
one-way ANOVA. Asterisks denote statistically significant differences, * P<0.05, ** 




































































Supplementary Figure S13: Assessment of body weight changes in mice injected 
with control or KMT2D-lacking pancreatic cancer cells. 
Body weight graphs of mouse xenografts bearing (i) MIAPaCa-2 or (ii) CAPAN-2 
shKMT2D#2-21b clonal cell lines and mock-transfected cells (n=5 mice per group). 
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Supplementary Figure S14: Effects of docosadienoic, docosatrienoic and 
docosatretraenoic acid on pancreatic cancer cell invasiveness in vitro.  
(A) Representative images of invading cells upon treatment with docosadienoic, 
docosatrienoic or docosatretraenoic acid for 22 h and (B) the respective quantification. 

















































Supplementary Figure S15: KMT2D staining patterns in matched pancreatic 
cancer and normal human tissues. 
(A) Representative images (4x magnification) of KMT2D expression as assessed by 
IHC analysis. Scale bars represent 40 μm. (B) Graphs for nuclear staining quantification 
of KMT2D expression in normal pancreata and matched tumors derived from Stage I or 
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Supplementary Figure S16: Correlation of KMT2D expression with overall patient 
survival. 
Kaplan-Meier survival curves of patients derived from Cohort III, harboring below 
median (<.25) and above median (>.25) KMT2D levels. 19 out of 22 cases were 
stratified as Stage III, 1 case as Stage IV pancreatic cancer and 1 case remains 
28 
 
uncharacterized. r, Pearson correlation coefficient; Statistical analyses were performed 
using Pearson correlation.  
SUPPLEMENTARY TABLES 
Table S1 















































Supplementary Table S1: Differential expression of chromatin regulators in 
pancreatic cancer. 
Table of standardized (Z-scores) expression of the corresponding histone 
methyltransferases (KMTs) and demethylases (KDMs) in pancreatic cancer as well as 
adjacent normal tissues originating from Cohort I, as assessed by DNA microarray 
analysis (Affymetrix U133 Gene ChIP Set). Multi-array analysis followed by filtering of 
uninformative and low variance probes revealed 8 epigenetic factors to be up- or down-
regulated ≥1.5 fold relatively to normal samples. Array fold change is generally reported 
























































































































































































































































































































































Supplementary Table S2: Xcelligence Cell Index and P values of siKMT2D#2-treated 
versus control MIA PaCa-2 cells.  
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
quadruplicates. Statistical analyses were performed using one-way ANOVA and the P values 
corresponding to the comparison of siRNA-treated versus control cells are shown at every 
single time point. P values ≤.05 are marked in red. Differences in Cell Index measurements are 



















































































































































































































































































































































Supplementary Table S3: Xcelligence Cell Index and P values of siKMT2D#2-treated 
versus control CAPAN-2 cells.  
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
quadruplicates. Statistical analyses were performed using one-way ANOVA and the P values 
corresponding to the comparison of siRNA-treated versus control cells are shown at every 
32 
 
single time point. P values ≤.05 are marked in red. Differences in Cell Index measurements are 














































































































































































































































































































































































































































































































































































































































Supplementary Table S4: Xcelligence Cell Index and P values of shKMT2D#2-21a versus 
mock MIA PaCa-2 cells. 
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
triplicates. Statistical analyses were performed using one-way ANOVA and the P values 
corresponding to the comparison of shRNA-stably transfected versus control cells are shown at 
every single time point.  P values ≤0.05 are marked in red. Differences in Cell Index 



































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S5: Xcelligence Cell Index and P values of shKMT2D#2-21a versus 
mock CAPAN-2 cells.  
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
triplicates. Statistical analyses were performed using one-way ANOVA and the P values 
corresponding to the comparison of shRNA-stably transfected versus control cells are shown at 
every single time point.  P values ≤0.05 are marked in red. Differences in Cell Index 







































Supplementary Table S6: Differential methylation of chromatin regulators in 
pancreatic cancer.  
Table of standardized (Z-scores) expression of the corresponding KMTs and KDMs in 
pancreatic cancer as well as adjacent normal tissues, as assessed by the Infinium 
Human Methylation 450 Bead ChIP Array. Wilcoxon rank-sum tests were conducted to 
compare methylation array data between pancreatic cancer patients and healthy 
controls. Genes shown are up- or down-regulated ≥1.5 fold relatively to normal samples 










12 49421179 49421179 G C intronic na na 
12 49422795 49422795 G A intronic na na 




12 49439659 49439659 C T intronic na na 


























12 49413208 49413208 - A UTR3 na na 
12 49415026 49415026 G A UTR3 na na 
12 49416048 49416048 C - intronic na na 
12 49419677 49419677 G C intronic na na 
12 49421179 49421179 G C intronic na na 
12 49422094 49422094 A G intronic na na 
12 49424616 49424616 G A intronic na na 
12 49424878 49424881 
TCT
G 
- intronic na na 












12 49436724 49436724 A G intronic na na 
12 49439521 49439521 A G intronic na na 
12 49439659 49439659 C T intronic na na 
12 49441382 49441382 T - intronic na na 
12 49442359 49442359 - A intronic na na 
12 49442813 49442813 T C intronic na na 





12 49448881 49448881 T G intronic na na 
 
Table S7: KMT2D mutational status. 
Sequence alterations in KMT2D gene, as assessed by Whole Exome Sequencng, in (i) 
MIA PaCa-2 and (ii) CAPAN-2 cell lines. Chr, Chromosome number; Start, Start 
position; End, End position; Ref, Reference base(s); Alt, Alternate non-reference alleles 
called on at least one of the samples; Func.refGene, Regions (e.g., exonic, intronic, 
non-coding RNA)) that one variant hits; ExonicFunc.refGene, Exonic variant function, 
e.g., nonsynonymous, synonymous, frameshift insertion; AAChange.refGene, Amino 
acid change. For example, KMT2D : NM_003482:exon38:c.A10671G:p.P3557P stands 











12 8072008 8072008 T C UTR3 na na 
12 8073496 8073496 T - UTR3 na na 




12 8075117 8075117 A G intronic na na 
12 8075286 8075286 C T intronic na na 
12 8083541 8083541 C T intronic na na 
12 8085547 8085547 T C intronic na na 
12 8086083 8086083 C A intronic na na 
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 8088227 8088227 T C intronic na na 
 8088766 8088766 T C UTR5 na na 
 
(ii) 






12 8072562 8072562 A G UTR3 na na 
12 8073496 8073496 T - UTR3 na na 




12 8075117 8075117 A G intronic na na 
12 8075286 8075286 C T intronic na na 
12 8086062 8086062 G C intronic na na 
12 8088766 8088766 T C UTR5 na na 
 
Table S8: SLC2A3 mutational status. 
Sequence alterations in SLC2A3 gene, as assessed by Whole Exome Sequencng, in (i) 















































































































































































































































































































































































































































































































































































































































Supplementary Table S9: Xcelligence Cell Index and P values of shKMT2D#2-
21a+siSLC2A3 versus shKMT2D#2-21a+siC#1 MIA PaCa-2 cells.  
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
triplicates. Statistical analyses were performed using one-way ANOVA and the P values 
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corresponding to the comparison of siRNA- transfected versus control cells are shown at every 
single time point. P values ≤.05 are marked in red. Differences in Cell Index measurements are 















































































































































































































































































































































































































































































































































































































































Supplementary Table S10: Xcelligence Cell Index and P values of shKMT2D#2-
21a+siSLC2A3 versus shKMT2D#2-21a+siC#1 CAPAN-2 cells.  
List of Cell Index values derived from the measured impedances and continuously displayed on 
the Xcelligence Software user interface. Each experimental condition was performed in 
triplicates. Statistical analyses were performed using one-way ANOVA and the P values 
corresponding to the comparison of siRNA- transfected versus control cells are shown at every 
single time point. P values ≤0.05 are marked in red. Differences in Cell Index measurements are 
significant after 36.1 hours of monitoring. 
 
Table S11 
Top Networks                                     
ID Associated Network Functions Score            Score 
 
Cell Cycle, Cell Death and Survival, RNA Post-Transcriptional Modification 
 
47 
Cell Morphology, Connective Tissue Disorders, Developmental Disorder 
 44 
Cellular Assembly and Organization, DNA Replication, Recombination and Repair, Cell Cycle 
 43 
Cancer, Endocrine System Disorders, Nervous System Development and Function 
 39 




Supplementary Table S11: Bioinformatics prediction of the top networks 
regulated by KMT2D.  
The list of the top 5 networks derived from IPA GO algorithms for the KMT2D-regulated 
genes (Figure 3G). “Score” refers to the numerical value used to rank networks 












.90 (1.11) 667 (540) 2828 
.85 (1.18) 706 (510) 1189 
.80 (1.25) 750 (480) 631 
.75 (1.33) 800 (450) 379 
.70 (1.43) 857 (420) 247 
.67 (1.50) 900 (400) 191 
.65 (1.54) 923 (390) 169 
.60 (1.67) 1000 (360) 120 
.57 (1.75) 1050 (343) 100 
.55 (1.82) 1090 (330) 88 
.50 (2.00) 1200 (300) 65 
 
 
Table S12: Sample Size Calculations. 
2-tail test has been conducted by the Mayo Clinic Pancreatic Cancer SPORE 
Biostatistics Core, for sample size calculations (Cohort V). To correctly reject a false null 





















Age at Diagnosis     .7052 
N 41 45 48 54  
Mean (SD) 64.78 (12.12) 64.53 (11.48) 64.98 (12.61) 63.15 (10.51)  
Median 67.00 66.00 64.50 62.00  
Q1, Q3 55.00, 75.00 55.00, 74.00 53.50, 75.00 57.00, 72.00  
Range (41.00-88.00) (37.00-81.00) (41.00-89.00) (43.00-92.00)  
      
Vital Status     .2316 
Missing 6 4 4 1  
Alive 8 (16.7%) 6 (11.8%) 2 (3.9%) 6 (10.9%)  
Deceased 40 (83.3%) 45 (88.2%) 49 (96.1%) 49 (89.1%)  
      
Survival (Days)      
N 30 39 39 50  
Events 25 35 37 44  














Year 5 N at Risk 4 2 7 8  
      
Sex     .2540 
Missing 6 4 4 1  
Female 21 (43.8%) 31 (60.8%) 24 (47.1%) 24 (43.6%)  
Male 27 (56.3%) 20 (39.2%) 27 (52.9%) 31 (56.4%)  
      
Race     .6593 
Missing 9 5 4 1  
1=American Indian/Alaskan Nativ
e 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.8%)  
2=Asian/Asian-American 1 (2.2%) 1 (2.0%) 0 (0.0%) 0 (0.0%)  
3=Black/African-American 0 (0.0%) 1 (2.0%) 0 (0.0%) 1 (1.8%)  
5=White 44 (97.8%) 48 (96.0%) 51 (100.0%) 53 (96.4%)  
      
Usual Adult BMI     .0252 
N 35 39 44 51  
Mean (SD) 27.01 (5.12) 27.59 (5.69) 30.21 (6.09) 29.67 (5.27)  
Median 26.63 28.34 29.32 28.80  
Q1, Q3 24.24, 29.23 23.81, 31.46 26.24, 32.03 25.06, 33.66  
Range (15.31-43.72) (16.46-38.80) (20.60-46.18) (18.88-43.02)  
      
Usual Adult BMI (<30,30+)     .1108 
Missing 19 16 11 5  
<30 28 (80.0%) 27 (69.2%) 24 (54.5%) 32 (62.7%)  
30+ 7 (20.0%) 12 (30.8%) 20 (45.5%) 19 (37.3%)  
      
Weight Loss     .0060 
Missing 6 4 4 1  
No 22 (45.8%) 21 (41.2%) 11 (21.6%) 11 (20.0%)  
Yes 26 (54.2%) 30 (58.8%) 40 (78.4%) 44 (80.0%)  
      
Pounds Lost     .0004 
N 48 51 51 55  

















Median 5.00 11.00 15.00 20.00  
Q1, Q3 0.00, 13.50 0.00, 22.00 7.00, 30.00 10.00, 30.00  
Range (0.00-40.00) (0.00-60.00) (0.00-85.00) (0.00-70.00)  
      
Stage at Surgery     .7224 
Missing 26 23 18 8  
IA 0 (0.0%) 0 (0.0%) 1 (2.7%) 0 (0.0%)  
IB 3 (10.7%) 3 (9.4%) 3 (8.1%) 3 (6.3%)  
IIA 5 (17.9%) 7 (21.9%) 13 (35.1%) 15 (31.3%)  
IIB 20 (71.4%) 22 (68.8%) 20 (54.1%) 29 (60.4%)  
IV 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.1%)  
 
Table S13: Quartile-based correlation of KMT2D expression with demographic 
and clinical characteristics of pancreatic cancer patients (Cohort V). 
Pancreatic carcinomas were subdivided in 2 groups: carcinomas with below median 
(<3.917) KMT2D expression and carcinomas with above median (>3.917) KMT2D 
expression. N: number of patients with clinical information; BMI: Body Mass Index. 
Clinical correlations were examined using the SAS software. 
 
Table S14 
Primer Sequence Tm (°C) 
FASN Forward CTT GGC CTT GGG TGT GTA CT 57.4 
FASN Reverse CTG ATC ATC AAG AGC CAC CA 54.6 
KMT2D Forward ATG CAG CCA AGG ACC TAG AA 56.4 
KMT2D Reverse ATG CCT CGA TTC TGC TCT TC 56 
KDM8 Forward TCA GTG CAG AGA GCC AGA GA 54.1 
KDM8 Reverse ATC GGC CTC GTG TAA CAA GT 55.9 
KDM4C Forward TGG ATC CCA GAT AGC AAT GA 53.1 
KDM4C Reverse TGT CTT CAA ATC GCA TGT CA 52.3 
KDM2A Forward CCT CAG TGG CAT CAT CAA GA 54.5 
KDM2A Reverse TTT CAG TCC TGG CAG CCT AT 56.1 
KDM5B Forward CCT TGC CAA ATG GAA AG AAA 51.5 
KDM5B Reverse CTT CCC CAA GAG TTG CCA TA 54.6 
KMT2B Forward ACT TCG AGG ACA TGG AGG TG 55.6 
KMT2B Reverse GCG GCT ACA ATC TCT TCC TG 55.6 
KMT2C Forward GAA TCA CTT CCT GGG GTT GA 54.5 
KMT2C Reverse GGC AAG AGG AAG TTC CAT GA 54.8 
RELA Forward CCA GAC CAA CAA CAA CCC CT 57.6 
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RELA Reverse TCA CTC GGC AGA TCT TGA GC 57.0 
SETD6 Forward GCT TTC AGG AAC CAC TGG AG 55.8 
SETD6 Reverse GGC GTT GTG ATT GGC TAA GT 55.8 
SLC2A3 Forward TCC ACG CTC ATG ACT GTT TC 55.1 
SLC2A3 Reverse GCC TGG TCC AAT TTC AAA GA 53.3 
SLC2A1 Forward GTG GAG ACT AAG CCC TGT CG 57.3 
SLC2A1 Reverse CAT AGC CAC CTC CTG GGA TA 55.8 
STK11 Exon 6 Forward TCG AAA TGA AGC TAC AAC ATC      50.7 
STK11 Exon 6 Reverse TTT CAG CAG GTC AGA GAG 51.3 
SUV420H1 Forward TCA ACT GGT CGA GAT ACA GCA 55.6 
SUV420H1 Reverse CTC CAA AGA ACC CAT CTC CA 54.3 
TSC1 Forward CTG GAG GAC TGC AGG AAC AT 56.9 
TSC1 Reverse GAG CAG CAG CTC AGT GTG AC 58.5 
β-actin Forward CCC AGC ACA ATG AAG ATC AA 57.1 
β-actin Reverse ACA TCT GCT GGA AGG TGG AC 53.0 
GAPDH Forward ATG TTC GTC ATG GGT GTG AA 54.4 
GAPDH Reverse GGT GCT AAG CAG TTG GTG GT 57.9 
 
Supplementary Table S14 Primers used in qPCR analysis. 
The list of all primer sequences used for real-time PCR analysis. 
 
 
SUPPLEMENTARY MATERIALS AND METHODS 
Cell Cultures and Treatments 
Pancreatic cancer cell lines (MIAPaCa-2, PANC-1, CAPAN-1, CAPAN-2, AsPC-1, 
BxPC-3, HPAF-II and CFPAC-1) were purchased from ATCC. MIA PaCa-2 and PANC-1 
were grown in DMEM, CAPAN-1 and CFPAC-1 in IMDM, CAPAN-2 in McCoy’s 5A, 
AsPC-1 and BxPC-3 in RPMI 1640 (Gibco), HPAF-II in EMEM (ATCC), all 
supplemented with 10% FBS (Gemini Bioproducts). In the case of MIA PaCa-2, medium 
was also supplemented with 2.5% horse serum (Gibco). STR analysis has been 
performed as a method for human cell line authentication. 
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Pancreatic cancer cells were plated (2.5*105 cells in 35mm dishes) and after 24 h were 
treated with 1 or 2 µM of 5-AZA-CdR (A3656, Sigma-Aldrich). Cells were incubated for 0 
to 4 days before DNA, RNA or protein extraction.  
Around 80% confluent MIA PaCa-2 cells were pretreated with 100 nM rapamycin 
(#1292, TOCRIS) for 24 h. Cell lysates were analyzed by IB analysis. 
KMT2D-silenced MIA PaCa-2 cells were treated with the inhibitors of NF-κB activation, 
Tanshinone IIA (4426) and RO 106-9920 (1778) purchased from TOCRIS, for 24 h 
before RNA extraction. 
MIA PaCa-2 cells were plated in 96-well dishes (1*103 cells/well) and treated with a) 
different doses of lipids including: cis-13,16-Docosadienoic (Hebei Zhongzhuo Import 
and Export Trade Co, Ltd), 13Z,16Z,19Z-Docosatrienoic (SC-200782, Santa Cruz 
Biotechnology, Inc) or 4,10,13,16-Docosatetraenoic acid (D3659, Sigma-Aldrich) and b) 
the lipid synthesis inhibitors SC 26196 (4189, TOCRIS) and SB 204990 (4962, 
TOCRIS). Cells were incubated for 1, 3 or 5 days before measurement of cell viability 
and for 3 days before performing in vitro invasion assays. 
 
Real-Time PCR Analysis 
RNA purified from cells and tissues with TRIZOL (Life Technologies) was reverse-
transcribed to form cDNA using the iSCRIPT RT Supermix (Bio-Rad), which was 
subjected to real-time PCR analysis using the iQ SYBR Green Supermix (Bio-Rad) on a 
CFX384 Touch Real-Time PCR Detection System (Bio-Rad). The primer sequences 
used for real-time PCR were acquired from previous studies [3] or designed using the 
NCBI Nucleotide Database (http://www.ncbi.nlm.nih.gov/nuccore), Primer3 v.0.4.0 
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(http://bioinfo.ut.ee/primer3-0.4.0) and UCSC In-Silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr) and are included in Table S14. Gene expression 
levels were normalized to the levels of GAPDH and β-actin. Normalized gene 
expression levels were quantified to the respective control. Bars represent means ± SE; 
experiments were performed in quadruplicates for each condition. 
For Kaplan-Meir studies in patients’ Cohort V, transcript expression for human KMT2D 
was determined using PerfeCTa SYBR Green FastMix (Quanta BioSciences 
Inc.,Gaithersburg, MD) and the following primer sets: KMT2D, 5’- 
AACCATATCGGCCTGGCATT -3’ (forward) and 5’- CAGCAGGTATCACCTCGTCG -3’ 
(reverse); 18S, 5’- AACCCGTTGAACCCCATTCGTGAT -3’ (forward) and 5’- 
AGTCAAGTTCGACCGTCTTCTCAG -3’ (reverse). 500 ng RNA was reverse 
transcribed using High Capacity cDNA synthesis kit (Applied Biosystems). 10 ng cDNA 
from each sample was used for qPCR analysis. Amplification was performed using the 
C1000 Thermal Cycler (Bio-Rad). RNA levels were normalized by comparison with the 
corresponding housekeeping RNA level in the same sample. The results are calculated 
following the 2ΔCt (where ΔCt represents the difference in threshold cycles between the 
target and control gene). 
 
Whole Exome Sequencing 
Genomic DNA was isolated from human MIA PaCa-2 and CAPAN-2 pancreatic cancer 
cell lines using QIAamp DNA Mini Kit (51304) and used for Whole Exome Sequencing 
that was conducted at the UCLA Clinical Microarray Core. The library construction was 
performed using the SeqCap EZ System from NimbleGen according to the 
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manufacturer’s instructions. Briefly, genomic DNA was sheared, size selected to roughly 
300 base pairs, and the ends were repaired and ligated to specific adapters and 
multiplexing indexes. Fragments were then incubated with SeqCap biotinylated DNA 
baits after LM-PCR and the hybrids were purified using streptavidin-coated magnetic 
beads. After amplification of 18 or less PCR cycles, the libraries were then sequenced 
on the HiSeq 3000 platform from Illumina, using 100-bp pair-ended reads. The 
sequence data were aligned to the GRCh37 human reference genome using BWA 
v0.7.7-r411. PCR duplicates were marked using MarkDuplicates program in Picard-
tools-1.115 tool set. GATK v3.2-2 was used for INDEL (insertions and deletions) 
realignment and base quality recalibration. Exome coverage was calculated using the 
bedtools. Samtools was used to call the SNVs (single nucleotide variants) and small 
INDELs. Varscan2 was used to call the somatic SNVs. All variants were annotated 
using the Annovar program. 
 
Immunoblot Analysis 
Total cell extracts were separated by SDS-PAGE and transferred to PVDF membranes 
following standard procedures. Frozen tissue biopsies were homogenized using RIPA 
buffer (Cell Signaling Technology), followed by sonication. In the case of KMT2D, 
protein levels were monitored by 5% SDS-PAGE using modified long apparatus for 
extended running time. Transfer time reached 24 h at 40C and the buffering system 
contained 15% methanol. The following antibodies were used for immunoblot analysis: 
KMT2D (R0118-1, Abiocode), mono-methyl-Histone H3 (Lys4) (5326), di-methyl-
Histone H3 (9725), tri-methyl-Histone H3 (Lys4) (9751), Histone H3 (14269), FASN 
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(3180), phospho-mTOR (Ser2448) (5536), mTOR (2983), RICTOR (2114), phospho-NF-
κB p65 (Ser536) (3033), NF-κB p65 (8242), CREB (9104) (Cell Signaling Technology). 
The protein levels that corresponded to the immunoreactive bands were quantified 
using the Scion Image analysis software (Scion Corp., Frederick, MD). 
 
Cell Viability Assay  
MIA PaCa-2 cells were plated in quadruplicates and treated with exogenously added 
lipids in 96-well plate (1*103 cells/well) and cell growth was assessed 1, 3 or 5 days 
later using the CellTiter Glo Luminescence Cell Viability Assay (Promega). Data are 
expressed as mean fluorescence (arbitrary units) ± S.D. 
 
Anchorage-Independent Cell Growth Assay 
Triplicate samples of 25*103 MIA PaCa-2 cells from each treatment were assayed in 48-
well plates for colony formation using the CytoSelect Cell Transformation kit (Cell 
Biolabs, Inc). Colorimetric quantitation of colonies has been performed according to the 




Invasion in matrigel has been conducted by using standardized conditions with BD 
BioCoat Matrigel invasion chambers (354480; BD Biosciences) according to the 
manufacturer's protocol. Assays for MIA PaCa-2 cells were conducted using 10% FBS-
containing media as chemoattractant. Noninvading cells on the top side of the 
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membrane were removed, whereas invading cells were fixed and stained with .1% 
crystal violet, 22 h after seeding. The cells that migrated through the filter were 
quantified by counting the entire area of each filter divided in four fields, using a grid and 
an Evos microscope at a X20 magnification. Data are expressed as the mean number 
of invading cells per field ± SD. 
 
Dynamic Monitoring of Cell Proliferation 
Real-time cell proliferation analysis based on the application of electrical cell substrate 
impedance changes 
(https://lifescience.roche.com/wcsstore/RASCatalogAssetStore/Articles/BIOCHEMICA_
4_08_p14-16.pdf) was performed using the xCELLigence RTCA instrument (ACEA 
Biosciences). The presence of cells affects the local ionic environment at the electrode 
solution interface. Cell status is represented by a dimensionless parameter termed Cell 
Index, which is derived as the relative change in measured electrical impedance, after 
subtraction of the background measurements from media alone. Local ionic 
environment varies according to cell size, cell morphology and strength of adhesion of 
the cells to the surface of the electrode, resulting in changes of the electrode 
impedance. 5*103 cells were seeded in quadruplicates of an E-Plate 96 with 
interdigitated microelectrode arrays integrated in the bottom of each well. Subsequently, 
the E-Plate 96 was mounted on the SP Station of the xCELLigence RTCA system which 
is placed in a standard temperature-controlled CO2 incubator under humidity saturation. 
The RTCA Software preinstalled on the RTCA control unit allows automatic selection of 
wells for measurement and real-time data acquisition within preprogrammed 15 min 
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time intervals.  Bars represent means±SD; experiments were performed in 
quadruplicates for each condition. 
 
Immunohistochemistry and Digital Pathology Analysis 
For immunohistochemical analysis of KMT2D in matched normal and cancer human 
tissues, deparaffinized 5-μm sections were incubated sequentially in accordance with 
the instructions of the LSAB kit (DAKO Corporation). For digital automated 
morphometry, the immunohistochemically stained sections were digitized at 40x 
magnification using an Aperio Scanscope CS (Aperio). The final immunohistochemical 
score was calculated from a combination of the intensity and percentage scores [4]. 
Antigen retrieval was performed by incubating the slides in boiling .01% sodium citrate 
pH 6.0 for 5 min. The endogenous peroxidase activity was inhibited by immersing the 
slides in 3% H2O2-methanol for 25 min and the background nonspecific binding was 
reduced by incubating with 1% BSA in PBS for 60 min. The slides were incubated 
overnight with antibody against KMT2D (1:200) (HPA035977, Sigma-Aldrich). In order 
to reduce the variability, all samples from each group were processed at the same time 
in a single experiment using a single batch of diluted antibody. The slides were then 
washed 5 times in PBS, followed by sequential incubations with biotinylated secondary 
antibody for 30 min at RT, streptavidin-HRP conjugate for 30 min at RT and 3,3'-
diaminobenzidine tetrahydrochloride (liquid DAB) for 3 min in the dark. The reaction was 
arrested with distilled water and the slides were counterstained with hematoxylin. 
Thereafter, the tissues were washed in tap water for 5 min, dehydrated through ethanol 
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baths (70, 90 and 100%) and xylene. Slides were finally mounted with E-2 Mount 
medium (Shandon lab). 
The Aperio Scanscope CS obtains 40X images with a spatial resolution of 0.45 
μm/pixels. The images were reviewed using an ImageScope (Aperio). Once the areas 
were recorded (500 μm for each tissue), they were sent for automated image analysis 
using the Spectrum Software V11.1.2.752 (Aperio). For the within tissue intensity, an 
algorithm was developed to quantify the total or nuclear protein expression. The output 
from the algorithm gives a number of quantitative measurements, namely the intensity, 
concentration and percentage of positive staining. The quantitative scales for the 
intensity and percentage were categorized into 4 and 5 classes, respectively, after the 
cut-off values were determined. The staining intensity was categorized as 0 (no 
staining), 2+ (moderate) and 3+ (strong). 
All other immunostainings of formalin fixed paraffin embedded (FFPE) sections have 
been performed by the Translational Pathology Core Laboratory, UCLA. The 
endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol 
for 10 min. Heat-induced antigen retrieval was carried out for all sections in .01M Citrate 
buffer, pH=6.0 by using a Biocare decloaker at 95oC for 25 min. The slides were 
incubated for 1h with antibodies against KMT2D (1:200) (HPA035977, Sigma-Aldrich), 
SLC2A3 (1:100) (20403-1-AP, Proteintech), phosphorylated NF-κB p65 (536) (1:100) 
(ab86299, Abcam) and Ki-67 (1:100) (M7240, Agilent). The signal was detected using 
Mach3 rabbit, HRP conjugated polymer for 30 min (Biocare Medical) and visualized with 
the diaminobenzidine reaction.  Images were further captured with an Axio Imager.Z1 
upright microscope (Carl-Zeiss). 
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HM450 Methylation array 
For global methylation profiling, the Illumina Infinium HumanMethylation450 (HM450) 
BeadChIP has been used (Illumina, San Diego, CA). Bisulfite conversion has been 
performed on 1 µg of genomic DNA from each sample using the EZ-96 DNA 
Methylation Kit (Zymo Research, Irvine, CA) according to the manufacturer’s 
instructions. Bisulfite-converted DNA was whole genome amplified and enzymatically 
fragmented prior to hybridization to BeadChIP arrays. The oligomer probe designs of 
HM450 arrays follow the Infinium I and II chemistries, in which locus-specific base 
extension follows hybridization to a methylation-specific oligomer. The level of DNA 
methylation at each CpG locus was scored as beta (β) value calculated as (M/(M+U)), 
ranging from 0 to 1, with 0 indicating no DNA methylation and 1 indicating fully 
methylated DNA. The data were extracted using Illumina Genome Studio Methylation 
Module and quantile normalized using ‘preprocesscore’ R package (https://cran.r-
project.org/). Of the 485,577 CpG probes on the array, we filtered out probes with high 
detection P values, probes with a SNP within 10 base pairs of the target CpG [5] and 
repeat regions and probes on X and Y chromosomes, leaving 371,478 probes. The term 
‘hyper-methylation’ was used when there was an increased DNA methylation in patients 
compared to controls and, the term ‘hypo-methylation’ was used when we observed a 
decreased DNA methylation in patients compared to controls.  
For statistical and bioinformatics analyses, Wilcoxon rank-sum tests were conducted to 
compare methylation array data between pancreatic cancer patients and healthy 
controls. Magnitude of DNA methylation changes was assessed using methylation beta 
values. Correction for multiple comparisons was performed using FDR (Benjamini-
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Hochberg) approach. A corrected P value, denoted as, ‘q’≤.05 was considered 
significant. The mean difference in betas, associated P and q values for chromatin 
modifiers are presented in Table EV1. 
 
Targeted Bisulfite Sequencing and Data Analysis 
Next-generation sequencing for the evaluation of DNA methylation at single-nucleotide 
resolution has been conducted by Zymo Research Corporation, Irvine, CA. Assays were 
designed targeting CpG sites in the specified ROI using primers created with Rosefinch, 
Zymo Research’s proprietary sodium bisulfite converted DNA-specific primer design 
tool. The primer sequences used are as follows: (Forward: 
TTTAGTTTATGTTTTTGTGTTAGGATTAGAA, Reverse: 
AATAAACATATAAATCTCTTTCTTAACACCAA). Sequence reads were aligned back to 
the reference genome using Bismark 
(http://www.bioinformatics.babraham.ac.uk/projects/bismark/), an aligner optimized for 
bisulfite sequence data and methylation calling (Krueger & Andrews, 2011). The 
methylation level of each sampled cytosine was estimated as the number of reads 
reporting a C, divided by the total number of reads reporting a C or T. Following primer 
validation, provided samples were bisulfite converted using the EZ DNA Methylation-
LightningTM Kit (D5030, Zymo Research) according to the manufacturer’s instructions. 
Multiplex amplification of all samples using ROI specific primer pair and the Fluidigm 
Access ArrayTM System was performed according the to the manufacturer’s 
instructions. The resulting amplicons were pooled for harvesting and subsequent 
barcoding according to the Fluidigm instrument’s guidelines. After barcoding, samples 
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were purified using ZR-96 DNA Clean & Concentrator™-5 (D4023, Zymo Research) 
and then prepared for massively parallel sequencing using a MiSeq V2 300bp Reagent 
Kit and paired-end sequencing protocol according to the manufacturer’s guidelines. 
Sequence reads were identified using standard Illumina base-calling software and then 
analyzed using a Zymo Research proprietary analysis pipeline. Low quality nucleotides 
and adapter sequences were trimmed off during analysis QC. Paired-end alignment 
was used as default. Index files were constructed using the 
bismark_genome_preparation command and the entire reference genome. The --
non_directional parameter was applied while running Bismark. All other parameters 
were set to default. Nucleotides in primers were trimmed off from amplicons during 
methylation calling. 
 
Plasmid Construction and in vitro Methylation 
Linear 300 bp DNA fragments between nt: -179 and +122 relatively to the transcription 
start site in the human KMT2D genomic region were constructed by Genewiz either in 
the wild type form (unmodified), or modified by a C to A mutation at CpG sites -29 (Mut 
1) or +145 (Mut 2) or both (double Mut). Artificial SacI and HindIII restriction sites have 
been incorporated using Native Taq Polymerase (18038-018, Life Technologies) and 
the following primers: sense, 5’-GTAGATCAGAGCTCACTTTCTTG-3’; antisense, 5’-
CTAGTCATAAGCTTTCCTTGTGC- 3’. The resulting PCR products were subsequently 
cloned into the pCR 2.1-TOPO vector (450641, Life Technologies) using the TOPO TA 
cloning kit (Life Technologies). The pCR 2.1 TOPO plasmids containing the KMT2D 
genomic inserts (hereafter referred to as TOPOKMT2D) were linearized with SacI 
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(R3156M, New England Biolabs) and in vitro methylated using SssI methylase 
(M0226L, New England Biolabs), which nonspecifically methylates all CpG 
dinucleotides. The efficiency of in vitro methylation was confirmed by resistance to 
cleavage by the methylation-sensitive restriction enzyme HpaII (R0171L, New England 
Biolabs) that has recognition site(s) in the analyzed regions and no sites within the 
sequence of pCR 2.1 TOPO vector. The linearized methylated and unmethylated 
TOPOKMT2D vectors were then digested with HindIII (R3104T, New England Biolabs) 
to excise the KMT2D inserts. After fractionation on a 1.8 % agarose gel, the DNA bands 
corresponding to 300 bp were cut from the gel, isolated using NucleoSpin® Gel and 
PCR Clean-up columns (Macherey-Nagel). To determine whether global or site-specific 
CpG methylation of the KMT2D genomic region affected gene expression in a reporter 
gene construct, the methylated and unmethylated control fragments were then ligated 
into the pGL4.82 [hRluc/Puro] Vector (E750A, Promega) between the SacI and HindIII 
restriction sites. The pGL4.82 [hRluc/Puro] plasmid is designed for high expression and 
reduced anomalous transcription. The vector encodes the luciferase reporter gene 
hRluc but lacks eukaryotic promoter and enhancer sequences. T4 DNA Ligase 
(M0202S, New England Biolabs) was used to perform the ligation reaction according to 
the manufacturer’s instructions, at 1:3 vector to insert ratio. The efficiency of ligation and 
equivalence of incorporated DNA into the methylated and unmethylated constructs were 
confirmed by agarose gel electrophoresis. For further validation, DNA sequence 
analysis across the multiple cloning site region located upstream of the hRluc gene was 
performed using RVprimer3 clockwise primer (E448A, Promega) by Genewiz. The 
effect of total methylation on the transcriptional activity of the inserted KMT2D 
62 
 
fragments was expressed as the relative change in reporter gene activity. Data were 
presented as the mean of Luminescence Units ± SE of 3 independent experiments 
performed in triplicates. 
 
Chromatin Immunoprecipitation, Sequencing and Analysis 
Chromatin immunoprecipitation was carried out using the SimpleChIP Plus Enzymatic 
Chromatin IP Kit (Cell Signaling Technology). Briefly, the chromatin fragments, derived 
from siC#1, siKMT2D#1 and siKMT2D#2 treated cells, were immunoprecipitated with 
antibody against tri-methyl-Histone H3 (Lys4) (9751, Cell Signaling Technology) at a 
ratio 1:50 or 1:100, respectively. After purification, libraries for next generation 
sequencing were prepared using NEBNext® ChIP-seq Library Prep Master Mix Set for 
Illumina® (E6240, New England BioLabs) and further analyzed using Illumina 
NextSeq500 system (single-end 75bp protocol). Both ChIP-seq and Bioinformatics 
Analyses were performed by the Center for Cancer Computational Biology, Dana-
Farber Cancer Institute, Boston, MA. Sequencing reads in fastq-format were aligned to 
the UCSC hg19 reference genome using BWA (version 0.7.9a bwa mem with default 
options). Duplicate reads were removed with Picard tools (v. 1.115) MarkDuplicates and 
were filtered to retain only primary alignments with samtools (v0.1.19, view command 
with -F 0x100 flag). ChIP-seq peaks were called using HOMER (v4.7) findPeaks by 
selecting matched input samples with default settings (Poisson P value of <=1E-4 and 
fold change >=4.0). Histone option was employed. Further, peaks were annotated using 
HOMER's annotatePeaks utility using the hg19 annotations database provided with the 
software. Analysis of differentially bound peaks was performed using HOMER's 
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getDifferentialPeaks command, which examines the distributions of reads to determine 
enrichment in a particular condition (Poisson P value <1E-4, fold-change >=4.0), 
suggesting a differentially bound peak. Plots of the distribution of distances to the 
annotated transcription start site were created directly from the annotated peak data 
provided as output by HOMER. Similar approach was applied for the pie charts 
representing the distribution of annotated peak features. Enrichment plots were 
constructed by comparing the read density (number of reads divided by the length of the 
peak region) in each of the experimental conditions for each set of peak regions. Read 
densities were found in both siC#1and siKMT2D conditions for all peak regions in the 
siKMT2D condition; enrichment values were calculated as the scaled difference 
between the densities. The increase in H3K4me3 read density (comparing siKMT2D to 
siC#1) was tested with a one-sided Wilcoxon signed-rank test (P<.001). Similarly, 
enrichment values were calculated in both conditions for the peak regions found in 
siC#1 condition (P<0.001). 
 
Luciferase Assay 
MIA PaCa-2 cells were transfected with the untreated or CpG MSssl-treated 
KMT2D/hRluc constructs and the pGL4.51 [luc2/CMV/Neo] (E1320, Promega) 
containing synthetic firefly luciferase luc2 gene. 48 h later luciferase activity was 
measured using the Dual Luciferase Reporter Assay System (E1960, Promega). Data 
were expressed ± SE of the mean of 3 independent experiments. 
In order to assess whether STK11 represents a direct transcriptional KMT2D target, 
MIA PaCa-2 cells were transfected with the LightSwitch RenSP reporter vector carrying 
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human STK11 promoter (S714439, SwitchGear Genomics) and the pLenti CMV Puro 
LUC (w168-1) (17477, Addgene) containing Luc reporter gene. At 24 h, the cells were 
transfected with siC#1 or siKMT2D#2 and 48 h later luciferase activity was measured 
using the Dual Luciferase Reporter Assay System (Promega). Data were expressed ± 
SE of the mean of 3 independent experiments. 
 
Metabolic Profiling 
Cellular metabolic rates were measured using a XF24-3 Analyzer (Seahorse 
Biosciences) by the Cellular Bioenergetics Core, UCLA. Cells were plated as a 
confluent monolayer in the Seahorse plate and left undisturbed for 24 h. Bioenergetic 
parameters were obtained in basal and after sequential injection of an ATPase inhibitor 
oligomycin (oligo), a mitochondrial uncoupler (FCCP) and mitochondrial inhibitors 
rotenone and myxothiazol (RM) in pancreatic cancer cells. Bars represent means ± SD; 
experiments were performed in quadruplicates for each condition. 
Lipids extraction from a) human cancer cells b) tumor tissues from mice bearing human 
pancreatic cancer xenografts and c) human biopsies, reconstitution in the solvent 
system suitable for analysis and quantitative evaluation of altered lipid profiles by LC-
MS analysis were performed by the Lipidomics Core Facility, Wayne State University. 
Lipid classes currently analyzed: FAs and total cholesterol. Bars represent means ± SD; 






NADP/NADPH-Glo™ Assay  
The bioluminescent homogeneous NADP/NADPH-Glo™ Assay (G9081, Promega) was 
used for detecting total reduced nicotinamide adenine dinucleotides phosphates 
(NADPH) in cells pretreated with siC#1, siKMT2D#1 or siKMT2D#2, following the 
manufacturer’s protocol. Bars represent means±SD; experiments were performed in 
triplicates for each condition. 
 
Lactate Assay  
The Lactate Assay Kit (MAK064, Sigma) was used to determine the lactate production 
in cells pretreated with siC#1, siKMT2D#1 or siKMT2D#2 based on an enzymatic assay, 
which results in a colorimetric (570 nm) product, proportional to the lactate present, 
according to manufacturer’s instructions. Bars represent means±SD; experiments were 
performed in triplicates for each condition. 
 
Glucose Uptake Assay  
The Glucose Uptake Assay Kit (MAK083, Sigma) was used to determine the glucose 
uptake in cells pretreated with siC#1, siKMT2D#1 or siKMT2D#, according to 
manufacturer’s instructions. The glucose analogue, 2-deoxyglucose (2-DG) used, is 
taken up by cells and phosphorylated by hexokinase to 2-DG6P. 2-DG6P cannot be 
further metabolized and accumulates in cells, directly proportional to the glucose uptake 
by cells. Briefly, 2-DG uptake is determined by a coupled enzymatic assay in which the 
2-DG6P is oxidized, resulting in the generation of NADPH, which is then determined by 
a recycling amplification reaction in which the NADPH is utilized by glutathione 
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reductase in a coupled enzymatic reaction that produces glutathione. Glutathione reacts 
with DTNB to colorimetric product TNB, which is detected at 412 nm. Bars represent 
means ± SD; experiments were performed in triplicates for each condition. 
 
Cholesterol Uptake Cell-based Assay 
Cholesterol Uptake Cell-based Assay Kit (Cayman Chemical) was used to study cellular 
cholesterol trafficking, following the manufacturer’s protocol. Cells were treated with 
siC#1 or siKMT2D#2 in culture medium containing 20 μg/ml NBD Cholesterol and 
incubated for 72 h. Detection of cholesterol uptake was assessed by fluorescence 
microscopy using Axio Observer.D1 inverted microscope (Carl-Zeiss). 
 
Patient Samples  
RNA and DNA were extracted from ‘normal’ (adjacent non-tumoral) and PDAC tissues 
using TRIZOL (Life Technologies) and (QIAamp DNA Mini Kit, Qiagen), respectively. 
Samples originating from Cohort I were used for Gene expression profiling that was 
conducted at the UCLA Clinical Microarray Core, while DNA methylation analysis using 
Infinium HumanMethylation450 BeadChIP assay has been performed at the 
Translational Genomics Core, Cambridge, MA. For validation of the Gene expression 
array data, tissues originating from Cohorts II and III were subjected to RT-qPCR 
analysis., while FFPE tissues (Cohort IV) were subjected to immunohistochemical 
analysis. For correlation of KMT2D expression with overall patient survival, human 
pancreatic tumors (Cohort V) were approved by the institutional review boards of Mayo 
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School of Medicine and informed consent was obtained from all patients prior to tissue 
procurement and subsequent analysis. 
 
Statistical Analyses 
Quantitative data were expressed as means ± SD or SE of the mean, as indicated, or 
as boxes and whiskers (minimum-to-maximum), using Origin 9.1 Software. Statistical 
analyses were performed using one-way ANOVA or Pearson correlation. P values of 
<.05 were considered statistically significant. 
Clinical correlations were examined using the SAS software. The Kaplan-Meier test was 
used for univariate survival analysis. The Cox proportional hazard model was used for 
multivariate analysis and for determining the 95% confidence interval.  
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